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ABSTRACT 
Oligodeoxynucleotides containing CpG motifs (CpG-ODNs) are known for their ability to 
stimulate vertebral immune system and provide protection against pathogens. Although CpG-
ODN provides protection against bacterial infections in chickens mechanisms of 
immunoprotection remains elusive. The objective of this study was to identify mechanisms of 
immunoprotection of CpG-ODN following in ovo delivery in chickens .  
In the second chapter, we provide the mechanistic insights into CpG-ODN induced 
protection against Escherichia coli (E. coli). Multiplex cytokine gene analysis using QuantiGene 
Plex 2.0® technique revealed that CpG-ODN upregulates both Th1 and Th2 cytokines, as well as 
pro-inflammatory cytokines in both spleen and lung. In our study, Lipopolysaccharide-induced 
TNF factor-alpha factor (Litaf) stands out in the cytokine profiles of spleen and lungs, 
underscoring its role in CpG-ODN induced protection mechanisms. Flow cytometry analysis 
showed a marked increase of T lymphocyte and antigen presenting cells (APC) as well as enhanced 
expression of CD40 by APCs in spleen and lung after CpG-ODN treatment. This study 
demonstrated for the first time that CpG-ODN provides protection in neonatal chicks against E.  
coli infections by eliciting cytokine responses and enriching the immunological niches in spleen 
and lungs.  
In the third chapter, we show that CpG-ODN induces a dose-dependent influx of 
macrophages, CD4+ and CD8+ T-cell subsets in spleen and lungs of chicks that correlates with the 
immunoprotection against E. coli. We observed a dose-dependent enrichment of the 
immunological niches, wherein 25 µg and 50 µg of CpG-ODN induced significant changes in the 
immune profile of both spleen and lungs that correlated with their ability to resist E. coli infection. 
In the fourth chapter, we report that in ovo delivery of CpG-ODN formulated with CNT or lipid-
surfactant potentiate the protective effect against E. coli infection. In conclusion, this study 
provides a greater understanding of cellular and molecular mechanisms for CpG-ODN induced 
antimicrobial immunity. And this significant advancement in the mechanistic insight will help in 
utilizing the full therapeutic potential of CpG-ODNs. Our work on CpG-ODN dose-dependent 
changes and enhanced protection against E. coli infection by nanoparticle formulations 
demonstrate the possible utilitization of CpG-ODN in the poultry industry as an alternative to 
antibiotics to prevent bacterial infections of neonatal chickens. 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Introduction 
There is continuous emergence of infectious diseases in food animal species.  Disease 
prevention and control strategies are focused mainly on immune-based methods such as, vaccines, 
immunotherapy and immune modulation. Though vaccines are well-known biological 
preparations to stimulate the immune system for improved disease protection, they are not 
available for all disease agents and may not be effective when an immediate response is required. 
Additionally, the routine prophylactic use of antibiotics is controversial because residues may 
persist and can lead to the emergence of antibiotic-resistant microbes (9). The occurrence and 
increasing spread of resistant bacteria are rendering current antibiotics progressively less effective. 
Thus, there is pressure to restrict the use of antibiotics in agriculture, due to the emergence of 
antibiotic resistance and its implications on treating infectious diseases in humans. Consequently, 
the Canadian broiler chicken industry voluntarily discontinued the use of Category I antibiotics 
commencing in May of 2014. Therefore, finding alternatives to antibiotics is a priority in the 
Saskatchewan and Canadian broiler chicken industries (43). Currently, immune modulators with 
immune-stimulatory activity are being evaluated for their potential to replace antibiotics. The 
vertebral innate immune system identifies pathogen-associated molecular patterns (PAMPs) by 
pattern recognition receptors (PRR), inducing immune responses against infections (211). Some 
common components in pathogens that act as PAMPs include lipopolysaccharides (LPS), 
peptidoglycans, lipoteichoic acids, mannose-rich glycans, flagellin, and their genomic nucleic acid 
(8) , Non-vertebral deoxyribonucleic acid (DNA) which contains comparatively higher amounts 
of unmethylated cytosine phosphodiester guanine (CpG) dinucleotides compared to vertebral 
DNA, act as a PAMP. Hence, these unmethylated CpG dinucleotides (CpG motifs) induce strong 
immunostimulatory activity in vertebrates (5). In recent years, synthetic CpG 
oligodeoxynucleotides (CpG-ODNs) with immunostimulatory properties, have been synthesized 
and are currently in wide use for anti-cancer therapy, allergy treatment, vaccine adjuvants and as 
an immune protective agent (162). Thus, CPG-ODNs as immunotherapeutic agents have great 
potential to replace antibiotics for the prevention of various types of infectious diseases in the 
poultry industry (105).  
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1.2 Overview of the avian immune system 
Most of the studies on the immune system of avian species have been conducted in chickens 
(279). The immune system of avian species is composed of a network of immune organs (lymphoid 
organs), immune cells, humoral factors (antimicrobial immunoglobulins (Ig) and other proteins), 
cytokines and chemokines (238). The composition and function of the avian immune system is 
almost similar to that of the mammalian immune system, although there are some important 
differences (280). The bursa of Fabricius, the key lymphoid organ of B lymphocyte lineage, is one 
of the unique features in avian species which is absent in mammals (279). Moreover, differences 
are seen in gut associated lymphoid tissues (scattered lymphoid tissue and cecal tonsils). In 
addition, the organization of splenic lymphoides and lymphatic nodules are different as compared 
to that of mammals. There are also differences reported in some avian toll-like receptors (TLR), 
defensins, cytokines and chemokines (153). Differences in the nature of Igs between avian and 
mammalian species is another feature that makes the avian immune system unique (88). They also 
lack functional eosinophils and the functional equivalent to mammalian neutrophils are called 
heterophils (153).  
 
1.2.1 Avian immune organs 
Similar to the mammalian immune system, immune organs of the avian immune system 
also consist of primary (central) and secondary (peripheral) lymphoid organs (231)   
 
Figure 1-1:  Avian immune organs.  (GALT = gut associated lymphoid tissue). Adapted from 
Structure of avian immune system Dr Fares El-Khayat, LinkedIn slide share. 
www.slideshare.net/ssuser662c3a/structure-of-avian-immune-system-dr-fares-elkhayat. Slide 5. 
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1.2.1.1 Primary lymphoid organs 
Primary lymphoid organs are sites where multiplication and differentiation of immune cells 
occur resulting in immunologically efficient effector cells (147). The primary lymphoid organs of 
birds are bursa of Fabricius and thymus where B and T lymphocytes are differentiated, respectively 
(88). Both organs differentiate from the epithelial anlage of the embryo (231). The clear distinction 
between B and T lymphocyte population differentiation sites have provided an excellent base for 
studying immunological concepts of the B and T cell lineages in avian species (59, 70, 87). During 
embryonic development hematopoietic stem cells enter the bursal and thymic anlages and later 
differentiate into mature B and T cells respectively (231). The yolk sac is proposed as the site of 
origin of these hematopoietic cells (87, 242).  
The bursa of Fabricius is a sac like structure that is an outgrowth of the cloacal epithelium 
located at the dorsal end of the hind gut in birds (279). Initially this structure was thought to serve 
as a receptacle for storing semen in hens (2). However, following many investigations on the role 
of this organ, Glick et al. 1956 and his colleagues reported that the bursa of Fabricius is involved 
in antibody mediated humoral immunity (98, 99). In contrast, the thymus, emerge as an epithelial 
outgrowth of the pharyngeal pouches at embryonic development. Chicken thymus is a multilobular 
organ which can form up to 14 lobes (88, 277) located on either side of the neck continuing into 
the thoracic cavity (279). The thymus is the site for T lymphocyte maturation and differentiation 
and is involved in cellular immunity (279).  
 
1.2.1.2 Secondary lymphoid organs 
Secondary lymphoid organs of avian species develop from the mesenchymal anlage of the 
embryo. It is composed of  spleen, mucosa-associated lymphoid tissue (MALT), mural lymph 
node, ectopic lymphoid tissue, pineal gland and bone marrow (231, 261). Antigen induced immune 
responses take place in secondary lymphoid organs (279), where the differentiation of 
immunologically active T and B cells mature into antigen specific effector cells (261).  
The avian spleen is considered as an important organ in systemic immunity. The major part 
of spleen development occurs after hatch when birds are exposed to antigenic stimuli (84). It 
contains red pulp and white pulp which are not clearly defined. In addition, avian spleen contain 
less red pulp compared to mammals and therefore the contribution to oxygen circulation is less 
prominent (231). Thus, it is more important in both innate and adaptive immunity as an immune 
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organ where phagocytosis of damaged cells and antigens occur. It also serves as a site for 
production, maturation, and storage of lymphocytes (231, 292). 
As birds lack organised lymph nodes as in mammals, lymphoid tissue is developed at 
locations where antigenic stimulation occurs. Mucosal surfaces are the initial and main sites where 
antigens are introduced. Hence, widespread MALT is seen in birds (146). Gut-associated lymphoid 
tissue (GALT) is an important component of MALT. Small lymphoid accumulations are seen 
along the intestines. Cecal tonsils, Peyer’s patches, Meckel’s diverticulum, esophageal and pyloric 
tonsils, lymphoid accumulations in the roof of pharynx and in cloaca are components of the avian 
GALT (27, 231). Respiratory, reproductive and head-associated lymphoid tissues, such as the 
Harderian gland (located in the orbit behind the eye), conjunctival and nasal lymphoid tissue are 
also parts of MALT (231, 261).  
Mural lymph nodules are organized accumulations of secondary lymphoid tissue which are 
located within or closely to the lymphatic vessels, mainly those of the limbs and neck of the 
chicken (261). Ectopic lymphoid tissue are seen in non-lymphoid organs such as, liver, pancreas, 
kidney, endocrine glands, gonads, the brain and spinal cord (231, 241). It has been shown that 
lymphoid foci are present in these organs as a compensation for the lack of lymph nodes in birds 
(261) and cause no functional disturbance to the non-lymphoid organs (231). Pineal gland in birds 
has a lymphoid component that is immunologically active and able to produce antibodies (53).  
 
1.2.2 Immune cells 
The immune system is activated and commences responses when there is antigenic 
stimulation. The response is as a result of teamwork between various immune cells such as, 
macrophages, B and T lymphocytes (279). 
 
1.2.2.1 Macrophages and dentritic cells  
Both macrophages and dendritic cells (DC) originate from circulating monocytes which 
are derived from myeloblast progenitors in the bone morrow (281).They are both considered 
professional antigen presenting cells (APC), in addition to B lymphocytes (157). 
Chickens do not have macrophages that are constitutively present in serosal membranes 
and peritoneal cavity as seen in common mammalian species. In chickens, an inflammatory 
stimulation is needed for macrophages to be recruited to these sites from the circulation (157, 262). 
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Macrophages are most commonly known for their phagocytic function which contributes to the 
innate immunity (250). Macrophages with phagocytic activity have also been observed during 
embryonic development in chicken embryos (146). Monocytes derived from bone marrow mature 
and differentiate into tissue macrophages once migrated to tissue sites. These macrophages become 
capable of antigen processing and presenting, leading to adaptive immunity (250). Macrophages 
may also secrete several immunoregulatory cytokines or metabolites in response to antigenic 
stimuli. Therefore, chicken macrophages are involved in pathogen recognition and destruction, 
modulation of innate immune responses and activation of the adaptive immune system.  
Immature DC are considered poor T cell stimulators, but can capture antigens by 
phagocytosis, macropinocytosis or endocytosis.  Once they are activated by PAMPs, they migrate 
out of non-lymphoid tissues into secondary lymphoid tissues where they complete their 
maturation. These mature DC express up-regulated major histocompatibility complex (MHC) 
class II and co-stimulatory molecules and are specialized in presenting processed antigens to T-
cells to initiate adaptive immune responses (336). 
 
1.2.2.2 Lymphocytes 
B lymphocytes are the main cells that mediate humoral immunity. When antigens are 
processed and presented in association with T helper (Th)-2 cells, it leads to the activation and 
differentiation of B cells into plasma cells which secrete antibodies specific to the antigen (242, 
279).  B cells use Ig as their signaling receptors and they are secreted upon activation. Three Ig 
classes are found in chickens: IgM, IgA and IgY (related to both IgG and IgE in mammals) (242). 
T lymphocytes are mediators of cell-mediated immune responses. T lymphocytes possess 
specific antigen receptors (T cell receptors (TCR)). Unlike B cell receptors, they remain bound to 
the cell. In birds, TCR1 with γ and δ chains (γ/δ TCR) and TCR-2 and TCR-3 with α and β chains 
(α/β TCR) have been identified. The majority of T cells bear α/β chains (242, 279). For successful 
antigen presentation, T cells require certain surface glycoproteins which bind to MHC molecules 
while the antigen epitope is bound to the TCR. CD4 and CD8 are two main surface glycoproteins 
on T cells that bind with MHCII and MHCI, respectively. CD8+ T cells are involved in cytotoxic 
cell lysis and therefore known as cytotoxic T cells (CTL). CD4+ T cells are also known as Th cells. 
They are further divided to Th1, Th2, Th17 and T regulatory (T reg) cells depending on their 
effector or regulatory function (242). 
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1.2.2.3 Natural killer cells 
Natural killer (NK) cells are regarded as a third lymphoid lineage (102) which has many 
features of cytotoxic T cells (152). In chickens NK cells have been described as large lymphocytes 
with electron dense granula (102). In chickens, NK cells are mainly seen in the intestinal 
epithelium and less frequently in blood and spleen as is in mammals. NK cell mediated cytotoxicity 
have been reported in spleen and blood cell populations (152). As in mammals, NK cell activity 
protects birds against various viruses and virus induced tumors such as Marek’s disease (102, 278). 
Accumulation of these cells in tracheal mucosa during early infection of Mycoplasma 
gallisepticum is another report that proves anti-microbial activity of NK cells in the respiratory 
system (94).  
 
1.2.2.4 Heterophils 
Avian heterophils are equivalent to neutrophils in mammals. They are considered as the first 
cells to arrive to the site of pathogen invasion. Inflammatory or infectious stimuli cause a 
significant heterophil influx to sites of interest (125, 152). Heterophils act as phagocytes, but lack 
myeloperoxidases as seen in mammalian neutrophils. Hence, their bactericidal activity by 
oxidative burst is insignificant. The granular content of heterophils are also different than in 
mammalian neutrophils (244). However, antimicrobial beta-defensins found in heterophil granules 
can kill a wide range of bacterial pathogens (125). Upon activation (by pathogens or cytokines), 
heterophils induce expression of pro-inflammatory cytokines such as, interleukin (IL)1, IL6 and 
IL18 (300). 
 
1.3 Role of the immune system in protection against infectious diseases 
Similar to mammals, exposure to antigenic stimulation triggers the immune system of birds 
(279). The immune system is mainly divided as innate and adaptive immunity based on the speed 
and specificity of immune response (238). Innate immunity act fast and provide protection to the 
host by a series of defence mechanisms and components. Adaptive immunity on the other hand is 
not immediate but more precise and develops memory, thus the consecutive exposure to the same 
antigenic stimuli will result in a strong and quicker immune response (74). However, the 
synergistic role of both innate and adaptive immunity are important in successfully defending the 
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host against disease causing agents. Antigens or pathogens are sampled and processed by 
specialized antigen presenting cells and presented to the adaptive immune system (B and T effector 
cells) where either the pathogen is destroyed or self-antigens are tolerated (157). 
 
1.3.1 Innate immune responses 
Innate immunity is considered the first line of defence followed by adaptive immunity. 
Even though innate immunity was earlier considered as a non-specific, scavenger system that 
fought invading pathogens, recent studies have shown that innate immunity is more complex and 
can be specific (153) and  involve in induction and modulation of the adaptive immune system 
(152). Components of the avian innate immune system are similar to that of mammals. It includes 
constitute barriers, innate immune cells, pattern recognition receptors, complement system, active 
chemical responses, antimicrobial peptides, cytokines and chemokines (152, 153). 
The physical barriers that contacts with the environment are considered as constitutive 
barriers. The normal flora present on body surfaces prevents pathogen colonization. In addition, 
cilia found in airways, fatty acids on skin, peristaltic movement of the gut, gastric acidic pH , 
mucus and antimicrobial peptides are considered to play an important role in preventing pathogen 
invasion (152). 
 
1.3.1.1 Pattern recognition receptors 
PRR are germline-encoded receptors in the innate immune system. They can recognise 
both exogenous (pathogens) and endogenous (molecules such as uric acid) antigens (153). PRR 
recognise conserved microbial products called PAMPs. This recognition of PAMPs allows the 
immune system to discriminate between self and non-self. And also between harmless non-self 
and pathogen-associated non-self (209). PRR are generally divided into two types depending on 
their location, as membrane bound (TLR) and cytoplasmic nucleotide-binding oligomerization 
domain (NOD) like receptors. These can be further categorised by function as signaling PRR and 
endocytic PRR (153). Among these PRR, TLRs are among the most studied receptors in 
immunology. A TLR, is a family of pattern recognition receptors expressed on innate immune 
cells that is crucial for recognition of microbial patterns (PAMPs) (209). Once a TLR is triggered 
by a specific PAMP several signaling pathways are induced. The NF-κB pathway, mitogen-
activated protein kinase pathways and type 1 interferon (IFN) pathways then initiates production 
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of pro-inflammatory cytokines, chemokines, type 1 IFNs and also induce co-stimulatory molecules 
(153). Ten TLR’s have been identified in chickens (TLR 1LA, 1LB, 2A, 2B, 3, 4, 5, 7, 15, and 21) 
(309). Among them, TLR2A, 2B, 3, 4, 5 and 7, are orthologs to TLRs found in mammals (40). 
Chicken TLR21 is an ortholog to TLR21 found in fish and amphibians (40). TLR 1LA, 1LB, TLR 
15 and TLR 21 are unique to birds (309). 
 
1.3.1.2 Complement system 
The complement system is activated and works in a cascade in response to recognition of 
microbes. This activation leads to opsonisation which enhance phagocytosis, induce inflammatory 
responses, enhance B and T cell responses and involves in cytolysis of target cells by forming 
membrane attack complexes (152). 
 
1.3.1.3 Active chemical response 
Active chemical responses in innate immunity includes, acute phase proteins (plasma 
concentration changes by 25% or more following inflammatory stimuli), C-reactive proteins, 
amyloid, fibrinogen, Mannan-binding lectin, fibronectin, haptoglobulin, transferrin-ovotransferrin 
and other components that are involved in destroying pathogens and adaptation of host 
environment (152). Defensins (only β-defensins) (337) and cathelicidin-like proteins are two types 
of antimicrobial peptides identified in chickens (152). 
 
1.3.1.4 Cytokines 
Cytokines are regulatory peptide mediators which are secreted by cells and act as 
extracellular signals which affect the actions of other cells, during both innate and adaptive 
immune responses (95, 153, 154). Cytokines are divided to sub families based on various factors, 
such as structure, function and receptor usage.  In chickens, there are less number of cytokine gene 
families  than in mammals (153). Chicken pro-inflammatory cytokines, which are produced by 
macrophages as a result of inflammatory response include IL1β, IL6, IL8 and IL17 (95). Th1 type 
cytokines are IL2, IL12, IL15, IL16, IL18 and IFNγ which are seen in immune responses to 
intracellular pathogens. Th2 type cytokines include IL3, IL4, IL5, and IL13 which are seen in 
immunity against extracellular pathogens. In addition, other cytokines such as, transforming 
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growth factor (TGF)-β, IL10, tumor necrosis factor (TNF)-α known as lipopolysaccharide-induced 
tumor necrosis factor-alpha factor (Litaf), type 1 IFNs (IFNα, β, κ and ω) are reported (95, 153).  
 
1.3.2 Adaptive immune responses 
Adaptive immunity is important to clear infections and for immunological memory when 
innate immune system is not sufficient. Adaptive immunity can be divided into two main 
categories as humoral immunity and cell mediated immunity. Once a pathogen is presented by an 
APC, to naïve T cells they become activated and start proliferating. The type of T cell activated 
(CD4+ or CD8+) is decided based on the antigenic peptide presented via MHCI or II and signaling 
of co-stimulatory molecules (153). 
 
1.3.2.1 Humoral immunity 
Humoral immunity is directed against extracellular pathogens such as, extracellular 
bacteria, extracellular protozoa and helminths (153). CD4+ T cells are activated when antigens are 
presented via MHCII molecules (only on APCs) to the TCR. Activated CD4+ T cells (T helper –
Th cells) have either effector or regulatory functions. CD4+ T cells of effector function can be of 
Th1 or Th2 type. Th2 cells activate B cells and mediate the production of pathogen specific 
antibodies. IL-4, IL-13 and IL-9 have been shown to be principal Th2 cytokines in chickens (242). 
Regulatory T cells (T reg) are involved mainly in reducing and suppressing excessive Th1 
responses (153).  
 
1.3.2.2 Cell-mediated immunity 
Cell mediated immunity is directed against intracellular pathogens such as, viruses, 
intracellular bacteria and intracellular protozoa (153). Antigens presented through MHCI 
molecules (found in all cells) bind to TCR of CD8+ T cells and result in the killing of the infected 
cells (cytotoxic T cell activity). In addition, Th1 cells activate cytotoxic T cells, NK cells, 
macrophages and other effector cells. Similar to mammals, IFNγ is the predominant cytokine in 
cell mediated immunity in chickens (242). 
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1.3.3 Mucosal immunity 
Similar to mammals, mucosal surfaces such as the intestinal, respiratory, and urogenital 
tracts are designed to prevent microbial invasion. The mucosal lining act as a physical barrier, 
while other defense mechanisms such as a low pH, secretion of soluble antimicrobial molecules 
like lysozymes, peptides like defensins and cathelicidins, and most importantly the microbiome 
play an important role in mucosal immunity (242). Intraepithelial lymphocytes (IEL) and lamina 
propia lymphocytes (LPL) are the two cell types produced in the main gut mucosa associated 
lymphoid tissue that involve in the first line of host defence. IELs are considered as important 
components in local cell mediated immunity with NK cell activity. Whereas LPLs are found to be 
B cell rich areas that produce Ig (47, 191). Similar to mammals, birds produce polymeric IgA 
(pIgA) by plasma cells in the lamina propria against infectious agents. Then it binds to a receptor 
at the basolateral surface of mucosal epithelial cells. These receptor-Ig complexes are then 
endocytosed and eventually transferred to the apical surface where secretory IgA (sIgA) is released 
into the mucosal lumen (331). Understanding the function and components of mucosal immunity 
can aid in improving vaccination of poultry as well as developing methods to enhance immune 
responses. 
 
1.3.4 Neonatal immunity 
The first few days after a chick is hatched can be very critical due to its sudden exposure 
to a large number of antigenic stimuli (87). At the time of hatch, the immune system of a chick is 
not fully developed and competent enough to provide full protection against pathogens. However, 
maternal immunoglobulins transferred through yolk will provide short-term protection against 
pathogens in developing embryos and at the neonatal stage (71).  
 
1.4 Common bacterial diseases in neonatal chickens 
Neonatal chickens are most susceptible to invasive pathogens during the first week post hatch 
due to their functionally inefficient immune systems (168). Several bacterial pathogens cause 
disease and loss to the poultry industry at this very young age. Escherichia coli, Salmonella and 
Enterococcus are a few of the most common bacterial species that cause infections and death in 
neonatal chickens. These infections can affect the entire flock, particularly in broilers where their 
life span is short.  
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E. coli infection (colibacillosis) is one of the main infectious causes of first week mortality. It 
causes death in newly hatched chicks due to septicemia. Surviving infected chicks develop yolk 
sacculitis and omphalitis (247), which will result in uneven growth in the chicken flock and more 
condemnation at processing . Although E. coli infections in adult chickens is usually considered 
as a secondary infection due to immunosuppression or poor management practices (23), it is an 
important primary infection in neonatal chickens. Most avian pathogenic E. coli serotypes have 
been isolated from intestinal tracts of neonatal chicks compared to chick embryos. (126). This 
finding shows that E. coli spreads horizontally and can be easily transmitted into large number of 
neonatal chicks with immature immune systems. Therefore, a successful method to prevent 
infection early in life is very important. 
Salmonellosis caused by Salmonella Enteritidis is another condition that cause disease which 
can lead to death mostly in young chicks whose lymphoid organs are not yet fully developed (316). 
In addition to the negative impact caused on chickens health, Salmonella contaminated poultry 
products pose public health threats (180). A recent study also showed that embryo mortality related 
infections with Enterococcus species have become predominant in western Canadian poultry 
hatcheries (156). Enterococcus is considered as an opportunistic pathogen that is found in the 
intestinal microflora of humans and birds. However, it can become pathogenic and infect hosts 
when their immune systems are weak (270). One study presented that Enterococcus faecalis 
together with E. coli infections were the main cause for first week mortality in layers (232). Thus, 
successful methods for controlling bacterial infections in young chickens in the poultry industry 
without the use of antibiotics have become a major concern to researchers, producers, and 
veterinarians. 
 
1.5 Immune stimulating agents as antibiotic alternatives for poultry 
Many economically important infectious diseases are well controlled by vaccination in the 
poultry industry. However, vaccination against all disease causing agents is not practical. On the 
other hand, the use of antimicrobials in food animal species has raised much concern at present. 
The excessive use of antibiotics to treat and prevent diseases in poultry has been practiced all over 
the world for many years. This led to the emergence of antimicrobial resistant strains of bacteria 
leading to health concerns in humans and animals. Taking these points into consideration, the 
Canadian poultry industry has developed an industry-wide approach to demonstrate responsible 
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antibiotic use. Preventive use of category I antibiotics (the most important for human medicine) 
were withdrawn from the Canadian poultry industry commencing on May 2014 (43). Therefore, 
alternative methods to protect neonatal chicks from bacterial diseases are being explored. At 
present, more attention is given towards developing immune stimulatory agents as alternatives to 
antibiotics (192). TLR agonists such as LPS, CpG-ODN (239, 295), flagellin (91) and 
peptidoglycan, synthetic double stranded ribonucleic acid (RNA) analog poly (I:C) (167) have 
been identified as potential immune stimulants in chicken. 
 
1.6 History of CpG-ODN 
Tumor regression following systemic bacterial infection has been observed for centuries based 
on personal accounts rather than facts or research. The first attempt of studying this type of effect 
of a bacterial infection was carried out by Dr.William B. Coley, a surgeon who observed a sarcoma 
in one of his patients. The tumor then disappeared following a high fever from an Erysipelas 
infection, now known as Streptococcus pyogenes (320). First, he used live cultures of streptococci 
and injected them directly to tumor sites in patients (54). It had some anti-tumor properties, but 
due to the toxic effect, he then used heat-killed streptococci (55). Though this was still toxic, 
significant tumor regression was observed. The preparation he used was later referred to as the 
Coley’s toxin and it was identified that the tumor regression was attributed to the bacterial 
endotoxins in the preparation (332). But as the original organism that Coley used did not produce 
endotoxins and still had anti-tumor activity, research continued to identify the causes of antitumor 
activity (320). After continuous work by many researchers, Tokunaga  et al. 1984, discovered that 
purified bacterial DNA of Mycobacterium bovis (i.e. Bacillus Calmette-Guérin (BCG)) had anti-
tumor activity and that DNA from bacteria, but not from vertebrates, can induce the production of 
interferons, activate NK cells and inhibit tumor growth in mice (312, 341). Later, two other groups 
reported that treatment of bacterial extracts with nucleases reduced or showed no immune activity, 
which confirmed that the immune-stimulatory properties are attributed to the DNA molecule (39, 
260). The ability of BCG to reduce the incidence of cancer was reported by Bast  et al. in 1974 
after it was given as a vaccine (25). Yamamoto et al. 1988  also found that DNA from BCG 
stimulated mouse spleen cells in vitro, resulted in the amplification of NK activity and production 
of cytokines such as IFN-α/β and –γ (340). Since then, BCG has been used for cancer therapy, 
more widely for the local treatment of bladder cancer (57, 235). DNA fractions isolated from BCG 
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and other bacterial species showed similar action. Several hypothesis were considered and tested 
in order to explain the difference between bacterial and vertebral DNA, such as the differences in 
(i) DNA molecular size, (ii) guanine (G) + cytosine (C) ratios, (iii) methyl cytosine and, (iv) 
sensitivity to DNase.  Nonetheless, the same group failed to prove any of them. These researchers 
were able to identify a more unique hexamer palindromic sequences in active DNA than inactive 
DNA which might be responsible for activation of the immune system (341). Parallel to these 
findings they reported that particular palindromic sequences with 5’- CG -3’ motif (s) can activate 
NK cells  which are more common in bacterial genomes compared to vertebrates or plants (177). 
Meanwhile, another team reported that the stimulation of murine lymphocytes with highly purified 
single stranded DNA from E. coli triggered B cell proliferation and immunoglobulin secretion than 
vertebral DNA (215). This was further proven by Krieg et al. 1995, who has contributed a great 
deal in understanding CpG and its immune mechanisms. B cell stimulation by bacterial DNA 
required unmethylated CpG dinucleotides. In addition, methylation of bacterial DNA with CpG 
methylase stopped mitogenesis in B cells (174). The fact that cytosines of CpG motifs are highly 
methylated in vertebrates than in microorganisms  were also reported around the same time (35). 
Wagner et al. 1999 reported that unmethylated CpG DNA that is released by pathogens during 
infection sends a ‘danger signal’ to the vertebral innate immune system which will provide a 
protective immune response and clear the pathogen (319). This potential of CpG DNA motivated 
scientists to produce synthetic CpG DNA. As a result, Krieg et al. 2002 and his team synthesized 
CpG-ODN with a nuclease resistant phosphorothioate (PS) backbone and showed that the 
synthetic CpG oligonucleotides can induce murine B cells to proliferate and secrete 
immunoglobulins both  in-vivo and in-vitro. The PS backbone was created by replacing the non-
bridging oxygen atoms at each of the phosphodiester (PO) linkages with a sulfur (171). Moreover, 
they reported that ODNs lost their immune stimulatory activity if the CpG is eliminated. Optimal 
B cell activation is seen with ODNs containing a CpG motif in which the CpG dinucleotide is 
flanked by two 5’ purines and two 3’ pyrimidines. This was the first time that unmethylated CpG 
motifs were identified as vital mediators of immune activation (174). Furthermore, by increasing 
the number of these stimulatory CpG motifs in an ODN, the activity of the ODN could be 
increased. Alongside the evolution of immune recognition of CpG DNA, pathogens also adopted 
counter strategies like reducing or suppressing the level of CpGs in their genomes to reduce 
immune recognition (171). Since the development of synthetic CpG-ODN, extensive research has 
14 
 
been conducted in various animal species to explore it’s mechanism of action and possible routes 
of application. Four major classes of CpG-ODN are identified depending on the structural and 
functional characters (Figure 1-2): Class A (type D) = CpG-ODN has a single CpG motif, a central 
palindromic PO and modified PS backbone, induce IFN-α production and APC maturation; Class 
B (type K)  = CpG-ODN are considered most stimulatory, contains multiple CpG motifs, a full PS 
backbone, activate B cells and TLR9 dependent NF-kB pathway; Type C CpG-ODN  = has 
combined features of class A and class B; and Type P  = CpG-ODN has a PS backbone with 
multiple CpG motifs  (36, 162, 171). 
 
Figure 1-2:  Types of CpG-ODN NTP - neucleoside triphosphate, O-phosphodiester, S- 
phosphorothioate). TCG – TCG dimer. Adapted from Li, Ruiqiao et al 2017, (187). 
 
1.6.1 Mechanism of action of CpG-ODN 
DNA from various organisms with little or no methylation of CpG motifs, such as yeast, 
nematodes, and molluscs induce strong B cell stimulation (298). This led to the theory that immune 
recognition of CpG motifs trigger protective immune pathways in a host that is similar to detection 
of endotoxins and other microbial products by PRR (171). Since unmethylated CpG motifs were 
identified as the immune stimulatory regions of bacterial DNA, research was directed in 
identifying the innate immune pathways, which recognise and respond to unmethylated CpG. 
 
1.6.1.1 Cellular uptake 
When CpG motifs were first reported that they can activate B cells in mice, the molecular 
mechanism of this activation was unclear. However, Krieg proposed that B cells do not appear to 
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have a CpG-specific membrane receptor. And when CpG-ODNS were attached to a solid support 
they did not induce immunity which showed that cellular uptake was a key feature for its activation 
(171). This was further proven by Manzel et al.1999 who reported that CpG-ODN coupled with 
streptavidin-coated latex, magnetic, gold or agarose beads did not show cellular uptake and showed 
no immune stimulation. These results proved that CpG-ODN needs to be internalized into cells in 
order to result in immune stimulation (206). It is known that ODN uptake is different in different 
subsets of lymphocytes. B cells and monocytic cells has shown the highest rate of uptake while T 
cells and neutrophils show lower rates (171). The cellular uptake of ODN derivatives is mainly by 
endocytosis (339) involving phosphatidylinositol 3-kinases (PI3Ks) (142). One study also showed 
that CpG DNA require endocytosis followed by endosomal/lysosomal compartmentalisation for 
immune activation. They proved this by using specific inhibitors of endocytosis and endosomal 
trafficking (5). A more recent study showed that mannose receptor 1 (MRC 1) is involved in CpG 
ODN uptake and trafficking in mice peritoneal macrophages (220). Studies have shown that uptake 
of ODNs depends on concentration. Cellular uptake is considered more efficient at low 
concentrations (<1 µM), where a major amount of ODNs are absorbed on to the cell surface and 
internalized by absorptive endocytosis in a more efficient manner (339). This endocytosis is 
suggested to be most possibly clathrin dependent (28). The same group of researchers revealed 
that, fluid-phase endocytosis (pinocytosis) facilitates cellular uptake of ODNs at higher 
concentrations (28).Once taken in to cells, ODNs are compartmentalised in endosomes (181, 352). 
Another study showed that ODNs are endocytosed into acidic vesicles and are transported to the 
cytosol and nucleus of cells (313) 
 
1.6.1.2 Activation of immune pathways 
It was assumed that there was a T cell independent B cell activation pathway that is 
triggered by CpG-ODN, and that microbial DNA might be providing co stimulatory signals to B 
cells that are bound to antigens to induce specific antimicrobial immune responses (174). The 
receptor responsible for this immune response was identified as TLR9. These studies showed that 
immune responses to CpG DNA, such as splenocyte proliferation, cytokine production from 
macrophages and maturation of dendritic cells were absent in TLR9 deficient (TLR9 -/-) mice. 
Therefore, it was proposed that this specific toll-like receptor in the vertebral immune system has 
evolved to distinguish between bacterial DNA from self DNA (135). Concurrent findings of 
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another group showed that human TLR9 is the receptor playing a critical role in CpG DNA 
mediated activation of human cells (307). Human TLR9 (hTLR9) is found predominantly in 
immune cell rich tissues, such as spleen, lymph nodes, bone marrow and peripheral blood 
leukocytes (51). The same group reported that human cells expressing TLR9 are stimulated by 
CpG motifs that are active in humans but not in mice and suggested that deviation between TLR9 
molecules causes species-specific differences in the recognition of bacterial DNA. TLR 9 receptor 
has been identified and showed to be involved in CpG DNA recognition in many animal species 
like, cattle , pig (282, 311), horse (351) and dogs (128). TLR9 is a protein that has a transmembrane 
domain. Studies have shown that TLR9 is localized in the endoplasmic reticulum (ER) in 
unstimulated cells and are transferred to endosomes once activated by CpG DNA (181, 183).  
Both double and single stranded DNA were suggested to be taken up by endosomal 
compartment of the cell and have the same intracellular location (30, 353). Once in the endosome, 
endosomal maturation is required for activation of immune pathways (120).This was proven by 
using substances such as, chloroquine, bafilomycin or monensin to block or interfere with 
endosomal acidification and/or maturation, where it resulted in absence in the immune stimulatory 
activity of CpG DNA (120, 345). All functionally characterized TLRs signal through a common 
pathway involving myeloid differentiation marker 88 (MyD88), IL1 receptor-activated kinase 
(IRAK), TNFR-associated factor 6 (TRAF6), TGFb-activated kinase 1 (TAK1), and the kinases 
of IkB (IKK), IkB, and NF-kB (306). These transcription factors are shown to directly upregulate 
cytokine and chemokine gene expression (3). As CpG DNA binds to TLR9 in endosomes, their 
co-localization within the same vesicles induces the recruitment of MyD88 to initiate signaling 
(306). B cells and plasmocytoid dendritic cells (pDC) are the two main types of cells in humans 
that express TLR9 and responds to CpG DNA (162). Following activation by CpG DNA these 
cells will establish an immunostimulatory cascade of events which will result in stimulation, 
maturation, differentiation and proliferation of other cells such as NK cells, T cells, monocytes 
and macrophages (21, 162, 296, 297). Subsequently these cells secrete pro-inflammatory cytokines 
like, IL6, TNF-α and IL18. Moreover, they create a Th1 type immune environment by secreting 
cytokines such as, IFNγ and IL12 (122, 164) (Figure 1-3). Later, it was also found that CpG-ODN 
can activate a TLR9-independent pathway initiated by two Src family kinases, Hck and Lyn, which 
trigger a tyrosine phosphorylation–mediated signaling cascade which leads to cytokine secretion 
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(269). A very recent study have shown that in ovo administration of class B CpG-ODN has the 
ability to induce cytokine responses in neonatal chicken spleen (266). 
 
 
Figure 1-3:  CpG-ODN mediated activation of the immune system.  Reprtinted from AM 
Kreig, 2003. 
 
1.6.2 CpG-ODN safety 
The immunostimulatory properties of CpG-ODN could lead to safety concerns if not used 
cautiously. The main potential risks can be development of organ-specific or systemic autoimmune 
diseases and septic shock (162). Studies show that production of autoantibodies against double 
stranded DNA is accelerated with high doses of bacterial DNA in animals prone to autoimmune 
diseases like lupus (170). In addition, bacterial DNA (CpG DNA) stimulates the production of IL6 
cytokine and reduce the apoptotic death of activated lymphocytes leading to persistence of self-
reactive lymphocytes progressing to autoimmune diseases (96, 196, 344). The increased 
production of pro-inflammatory cytokines (TNF, IFN-γ) due to CpG-ODN could result in septic 
shock if reached extreme levels (162).  
Several studies focused to investigate the safety concerns of CpG-ODN. The toxicities 
observed in these studies all appear to be related to the chemical class, PS, and dose administered. 
Cardiovascular collapse and death was reported in primates due to complement activation and 
hemodynamic changes when very high doses of PS ODN was given (184). Another  study where 
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bacterial DNA containing unmethylated CpG motifs were injected to knee joints of mice showed 
that it can induce arthritis (75). Similarly, a different group of scientists reported that when CpG-
ODN were administered daily up to three weeks, disruption of lymphoid tissue, hepatic damage 
and hemorrhagic ascites could be seen in mice (134). 
However, repeated administration of CpG-ODN (two to four times/month) protected mice 
from challenge by Listeria monocytogenes and Francisella tularensis and these ODN-treated 
animals remained healthy and developed neither macroscopic nor microscopic evidence of tissue 
damage or inflammation. (163). Also, when CpG DNA was injected in doses equal or above the 
levels normally used as vaccine adjuvants every week up to four months to BALB/c mice, animals 
did not show any adverse effects and remained physically healthy (166). This indicates that even 
repeated CpG-ODN administration was safe in mice when used with caution. No toxicities or 
adverse effects were recorded in normal animals when CpG ODN was used as an immune 
protective agent, vaccine adjuvant or an anti-allergen.(162). A study that compared several 
adjuvants claimed that CpG DNA induces stronger immune responses with less toxicity than other 
adjuvants (327).  
 
1.6.3 CpG-ODN applications 
Though CpG-ODN was initially identified as an anti-tumor agent, at present, other 
potential applications of CpG-ODN are under investigation such as; induction of protective 
immunity against infectious diseases, stimulation of the immune system as a vaccine adjuvant and 
induction of anti-allergy immunity (162) (Figure 1-4). 
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Figure 1-4:  Therapeutic uses of CpG-ODN.  Reprinted from DM Klinman, 2004. 
 
1.6.3.1 CpG-ODN as an immune protective agent 
Earlier, the innate immune system was considered of less importance in the prevention of 
infectious diseases. However, at present the importance of innate immunity is studied vastly (210). 
CpG-ODNs can induce an innate immune response that can protect hosts from infectious agents. 
CpG DNA can elicit plasmacytoid dendritic cells (pDCs) to secrete type 1 IFNs which has a 
negative effect on a broad range of viruses and bacteria (141, 199). Therefore, the possibility of 
using CpG-ODN alone to reduce infections were considered (162). Many studies have been 
directed towards studying this theory in many animal species, especially using murine animal 
models. Mice were injected with CpG-ODN or bacterial DNA prior to challenge with an infectious 
agent of interest. These studies have shown that mice are protected from many bacterial infections 
like, Pulmonary Klebsiella (76), listeria and tularaemia (163, 173), acute polymicrobial sepsis 
(329)  viruses like, herpes (18, 249), cytomegalovirus (144), influenza (79) and parasites like, 
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leishmania (321, 354) and malaria (109). This immune protection lasted for about two weeks in 
mice when only a single CpG-ODN dose was injected (85). However, repeated administration of 
CpG-ODN showed significantly improved host resistance to infection for a prolonged period 
(163). A recent study showed that type-A CpG-ODN can induce high amounts of IFN-α in pDCs 
and thereby significantly reduced disease severity in experimental autoimmune encephalomyelitis 
which is a condition that mimics human multiple sclerosis. It also delayed onset of neurological 
deficits and reduced spinal cord demyelination, while increasing the percentage of splenic 
regulatory T cells (60).  
Many studies done in different species of animals have now shown the immune protective 
effect of CpG-ODN (38, 105, 182, 193, 228). Yet, studies on immune protective effect of CpG-
ODN in humans are not reported due to limitations of conducting challenge studies. However, 
Non-human primate studies gained interest by researchers, one study showed that susceptibility of 
normal rhesus macaques to infection with leishmania was significantly reduced by treatment with 
CpG-ODNs (317). 
 
1.6.3.2 CpG-ODN as a vaccine adjuvant 
Many of the successful vaccines are live, attenuated versions of the targeted pathogen 
where there can be mild disease when administered, or killed, recombinant or synthetic vaccine 
antigens that cannot act alone and need co-stimulation using an adjuvant (52, 245). CpG-ODNs 
activate cells that express TLR9 and induce an innate immune response by the production of pro-
inflammatory cytokines and Th1 type immunity. In addition, CpG-ODNs improve the maturation 
and activation of professional antigen-presenting cells and enhance the generation of humoral and 
cellular vaccine-specific immune responses when used as a vaccine adjuvant (36). 
Currently, CpG-ODN is being used as an adjuvant in vaccines produced for many animal 
species including humans (58, 69, 121). It has been used as an adjuvant in vaccines developed 
against toxins (tetanus, diptheria), bacteria (Brucella, anthrax, tuberculosis), viruses (measles, 
hepatitis, cytomegalovirus, influenza) and parasites (malaria, leishmania, trypanosome) [reviewed 
by (162)]. Inclusion of CpG-ODN as an adjuvant with leishmania promastigotes increased the 
level of IFNγ production, CD4+ and CD8+ T cells by 2–3 fold in mice compared to the mice that 
got the promastigotes alone (212). Another study showed that combining CpG-ODN with anthrax 
vaccine adsorbed (AVA - the licensed human vaccine) generates high levels of toxin neutralizing 
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antibodies very rapidly and challenged macaques (with anthrax spores) immunized with AVA plus 
CpG-ODN mounted a 3-fold stronger immune response than animals immunized with AVA alone 
(165). Furthermore, CpG-ODN have proven to enhance both mucosal and systemic immune 
responses with intra nasal mucosal administration of a hepatitis B (208) and influenza (218) virus 
antigens in mice. Some studies showed that CpG-ODN can induce an effective Th1 type immunity 
when used as an adjuvant in neonatal mice, which is a challenging age for vaccination as neonatal 
immune systems are not well developed (216). The safety of using CpG-ODN as a vaccine 
adjuvant has also been taken in to consideration. A study that evaluated several commonly used 
adjuvants found that CpG-ODN induces a stronger immune response with less toxicity than other 
adjuvants (327). Several studies reported about the safety of using CpG-ODN as an adjuvant (121, 
248). For example, safety evaluation of a CpG 7909, a class B CpG-ODN which was used as an 
adjuvant together with a commercial trivalent killed split influenza vaccine for humans showed 
normal values on physical evaluation, laboratory blood assays, and assays for DNA autoimmunity. 
The vaccine was well tolerated and induced a good immunity resulting in significantly higher 
levels of IFNγ secretion from peripheral blood mononuclear cells recovered at 4 weeks (58). 
Several studies in humans have shown the successful immune enhancement of vaccines with the 
use of CpG-ODN 7909 (VaxImmune™). A phase 1 clinical trial demonstrated the AMA1 (asexual 
blood-stage merozoite surface antigen Apical Membrane Antigen 1)-C1/Alhydrogel + CPG 7909 
vaccine provide an adequate safety profile and was highly immunogenic in malaria-naïve 
individuals (223). More phase 1 clinical trials showed the striking improvement of the immune 
response to BioThrax® (Anthrax Vaccine Adsorbed) AVA by CPG 7909 in healthy volunteers 
(138, 263). Adding CpG-ODN to the human influenza vaccine Fluviral® have shown to induce 
higher virus-specific antibody titers resulting in better protection in ferrets as manifest by a 20% 
reduction in viral load when compared to Fluviral® alone (86). 
 
1.6.3.3 CpG-ODN as an anti-tumor agent 
The accidental discovery of tumor curing ability of bacterial extracts was a significant 
milestone in the discovery of CpG-ODN. Over the years since its first discovery, many scientists 
have worked on understanding the mechanism of cancer curing ability of CpG-ODN. The well-
established theory is that the immune cascade that is induced by CpG-ODNs activate NK cells and 
CTLs which destroys cancer cells and facilitates the remission or treatment of cancer (162). One 
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study where mice were implanted with syngeneic GL261 glioma (a brain tumor model) showed 
that CpG-ODN induced TLR 9 down-regulation, followed by apoptosis of GL261 cells in vitro 
and in vivo. They also showed that CpG-ODN enhanced the antigen presenting capability of 
microglia and pronounced CD8+ T cell mediated immunity suggesting that CpG-ODN could be 
used for immunotherapy for treating malignant glioma (16). Another study using a colon 
carcinoma mice model also showed that CpG-ODN stimulated DC maturation and T cell activation 
which resulted in delayed or reduced tumor growth (42). Similar results were published by another 
group where peritumoral CpG-ODN injections to mice with colon carcinoma elicits a strong CD8 
T cell response and innate effector mechanisms that could cure tumors (133). In addition to its 
prophylactic and therapeutic use, CpG-ODN has been evaluated as an adjuvant in tumor vaccines. 
Mice immunized with CpG-ODN as an adjuvant were protected from tumor challenge (38C13 B 
cell lymphoma), similar to mice immunized with complete Freund’s adjuvant. However, with 
CpG-ODN less toxicity and a higher titer of antigen-specific Immunoglobulin gG2a (IgG2a) was 
observed than with complete Freund’s adjuvant (330). Similarly, human exosomes combined with 
CpG-ODN as an adjuvant efficiently activates naive CTLs leading to tumor (melanoma) rejection 
in transgenic mice (48). A number of preclinical studies showed that intra-tumoral injections of 
CpG-ODN elicited a stronger protective response than did systemic delivery of the same agent 
(44, 284). A very recent study showed promising results with reduction in tumor sizes in patients 
with B-cell lymphoma with a novel Class C CpG-ODN (SD-101) given with low dose radiation in 
a phase 1/2 trial (185). The development of an inhaled CpG-ODN, DV281 as immunotherapy for 
lung cancer is suggested very recently (92). 
 
1.6.3.4 CpG-ODN for anti-allergy therapy 
Allergic reactions, such as allergic asthma is caused by overproduction of Th2 type 
cytokines. The capability of CpG-ODNs to stimulate a Th1 immune responses that 
inhibits/balances the development of Th2 cell-mediated allergic response has been the key to using 
CpG-ODN as an anti-allergic agent (162). Several studies have been conducted on asthma models 
of mice to investigate the potential use of CpG-ODN for treatment of asthma. Sur and his group 
examined the ability of unmethylated CpG-ODN, to prevent the allergic asthma in mice sensitized 
to ragweed allergen. They reported that when CpG-ODN was administered 48h before allergen 
challenge there was an increase in the ratio of IFNγ to IL4 secreting cells, reduced allergen-induced 
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eosinophil recruitment, and less ragweed allergen-specific IgE producing cells. Furthermore a 
strong Th1 response resulted in less peribronchial and perivascular lung inflammation, and 
inhibition of bronchial hyper responsiveness 6 weeks after administration of CpG-ODN (299). In 
another study, mice were sensitized with conalbumin (model of asthma) and they reported the 
potential use of CpG-ODN for treatment of allergic asthma by suppressing Th2 responses during 
IgE dependent allergic airway reactions (276). A similar study that sensitized mice to Schistosoma 
mansoni eggs also looked at the effect of CpG-ODN. They reported that the group which received 
CpG-ODN + Schistosoma eggs showed less eosinophilia and reduced inflammation than the group 
that received the Schistosoma eggs alone. They also suggested that CpG-ODN is desirable than 
cytokines, such as IL12, as a therapy for asthma, due to its low cost, stability, safety, and induction 
of prolonged expression of cytokines (161). CpG-ODN has also been shown to be effective in 
controlling both early and late phases of allergic conjunctivitis in mice when administered either 
systemically or mucosally (203). CpG-ODN has been considered to be used as an adjuvant in 
allergen specific immunotherapy. A clinical trial conducted in humans reported that subcutaneous 
application of house dust mite allergen, together with A-type CpG-ODN packaged into virus like 
protein, reduced rhinitis and allergic asthma significantly in patients and was safe to use (275). A 
recent study showed that targeted treatment of allergic rhinitis with intra-nasal CpG-ODN reduces 
lower airway inflammation (186). 
 
1.6.4 CpG-ODN application in veterinary species 
Many studies have proven that bacterial DNA is recognized by immune systems of fish, 
birds and a variety of mammalian species [reviewed by (162)]. One group studied a number of 
important livestock, companion and laboratory animal species (sheep, goat, horse, pig, dog, cat, 
chicken, cotton rabbit, mouse and rat) and reported the active CpG motifs for the first time in each 
species. Moreover, based on their data, it was clear that CpG motif recognition is highly conserved 
in a broad variety of species. In all species they tested, the “GTCGTT” motif appeared to have 
stimulatory potential. The chemical nature of the backbone of the CpG motif also played a role in 
stimulatory capacity (254). Many studies have shown the potential use of CpG-ODN as an immune 
protector, vaccine adjuvant, anti-allergy and anti-tumor therapy in veterinary species. 
As neonatal immune systems are immature and highly vulnerable to diseases, one study 
investigated the ability of CpG-ODN to protect newborn lambs following aerosol challenge with 
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bovine herpesvirus-1, a respiratory pathogen. They showed that CpG-ODNs effectively activate 
innate immune responses in newborn lambs and induce antiviral responses which correlated with 
a reduction in viral shedding (229). Most studies on CpG-ODN immune activation and possible 
uses have been conducted in mouse models (16, 68, 161, 354). Similarly, immune activation by 
CpG-ODN and its various potential uses have been investigated in other animal species such as, 
cattle (255, 326) , pigs (175, 195), horses (200), rabbits (140), dogs (178), cats (257), non-human 
primates (150, 317) and birds (105, 202, 302). Several studies have also shown the immune effects 
of CpG-ODN in fish (38, 45, 308) and in fish vaccines (155). 
 
1.6.5 CpG-ODN applications in chickens 
Despite the absence of TLR9 in birds, which identify CpG-ODN in mammalian species, 
immune stimulation by CpG-ODN has been shown by several studies in chickens (63, 105, 301, 
324). This led to studies directed towards identifying the receptor which is responsible for CpG-
ODN mediated immune stimulation. 
DNA high in unmethylated CpG motifs is immunostimulatory through avian TLR21 which 
is absent in mammals. This was confirmed by showing expression of TLR21 resulting in marked 
NF-kB activation upon stimulation with exogenous ODN and confirmed that chicken TLR21 acts 
as a functional homologue to mammalian TLR9 in the recognition of CpG ODN (41). A similar 
study on TLR21 by another group also recognised chicken TLR21 as an innate CpG DNA receptor 
that is distinct from mammalian TLR9 (159). Chicken harderian gland cells have shown  up 
regulated expression of TLR21 and IFNγ with class B CpG-ODN stimulation (50). Immune 
stimulatory effects of CpG-ODN in chickens have been demonstrated in many in vitro and in vivo 
studies (240, 318). Immune modulation, as an immune protector or a vaccine adjuvant by CpG-
ODN in chickens have been investigated related to common bacterial diseases such as,  E. coli 
(103-105) , Salmonella (131, 132, 202, 301), Campylobacter (304, 305); viral diseases such as, 
infectious bronchitis (65, 66), infectious bursal disease (204, 324), Newcastle disease (194, 350), 
avian leukosis virus (80) avian influenza virus (289-291), infectious laryngotracheitis (310); 
protozoan diseases such as, coccidiosis (63, 64). Intra pulmonary delivery of CpG-ODN has shown 
protective immunity against E. coli in neonatal chickens suggesting its use as an alternative to 
antibiotics (106).  
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1.6.5.1 CpG-ODN as an immune modulator in chickens 
In modern poultry practices, broiler chickens reach market weight at about 35-42 days of 
age, therefore, the first days of a broiler chickens life is very important. During these first days of 
life neonatal chicks are exposed to a new environment and their immune systems are not fully 
functional, causing them more susceptible to diseases. Therefore, improving the immune response 
and disease resistance of these immature chicks is vital for survival and performance up to their 
market age (347). Additionally, stimulating the immune system and taking prophylactic measures 
rather than having to use therapeutic dosages is superior from a food safety and public health 
viewpoint (105). Thus, CpG-ODNs were considered as an ideal immune modulator. Gomis et al. 
2003 reported the immunoprotective effect of CpG-ODN against an extracellular bacterial 
infection in chickens for the first time. At 22 days of age, broiler birds received CpG-ODN by 
either the subcutaneous (SC) or intramuscular route (IM). Three days later, a virulent isolate of E. 
coli was applied to a scratch site on the caudal abdominal skin and examined for 10 days. Groups 
that received CpG-ODN by either SC or IM injection had significantly higher survival rates 
compared to the control group. In addition, the cellulitis lesion caused by E. coli was also smaller 
in CpG-ODN received group. This was the first time the immune protective effect of CpG-ODN 
was demonstrated in any food animal species (105). Similarly, the potential use of CpG-ODN as 
an immune protective agent against an E. coli infection was demonstrated by the same group in 
neonatal broiler chickens (104). Thereafter, the immune protective effect of CpG-ODN was 
demonstrated by several studies by many other researchers in chickens (63, 65, 301). 
 
1.6.5.2 In ovo CpG-ODN administration in chickens 
The first automated egg injection system was introduced in 1992 (Inovoject). This method 
of directly injecting substances like a vaccine or drug in to the egg replaced the conventional 
method of vaccinating newly hatched birds by subcutaneous injection. There are many advantages 
of in ovo vaccination compared to post-hatch vaccination, which include earlier immunity (in 
vaccines like Marek’s), reduced bird stress, precise and uniform injection, reduced labor costs, and 
reduced contamination (258). 
As in ovo technology was already in use in the poultry industry. CpG-ODN delivery by this 
method was considered to activate immune systems of neonatal chickens and prepare them to fight 
diseases in their first weeks of life. Thus, for the first time Gomis et al. 2004 showed that in ovo 
26 
 
delivery of CpG-ODN protected neonatal chicks against a bacterial infection. (104). Similarly the 
immunoprotective effect of CpG-ODN when given by the in ovo route has been investigated in 
several studies (65, 202, 301, 310). The potential use of CpG-ODN as an in ovo vaccine adjuvant 
in chickens was also studied (64, 78). These findings directed researchers to further explore 
methods to develop efficient CpG-ODN delivery systems in chickens that could be applied in the 
modern poultry industry. 
 
1.7 Nano particle based drug delivery systems 
The development of novel drug/gene delivery systems involving nanotechnology has become 
a popular field over the years. These are delivery systems of nanometer scale complexes (10–1000 
nm) consisting of an active therapeutic ingredient and a carrier material (73). Nanoparticles (NP) 
based drug delivery systems are well known for their controlled and targeted release of a drug/gene 
(256). In these delivery systems, the nanoparticle act as a vehicle where the drug of interest is 
dissolved, entrapped, adsorbed, attached and/or encapsulated into or onto a nano-matrix (288). 
Many categorization systems are used to classify different nanoparticle types by many researchers. 
However, depending on the material composed these nanoparticle types can be simply divided as 
(i) metal based, (ii) lipid based, (iii) polymer based (iv) carbon nanotubes and (v) biological 
nanoparticles (56) . 
 
Figure 1-5:  Commonly used nanoparticle types based on composition. Adapted from Conniot 
et al 2014,(56). 
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1.7.1 Nanoparticle systems 
 
1.7.1.1 Metal based  
Metal based systems – metals such as, gold, silver, palladium and platinum are commonly used 
for drug delivery (139). The extreme small size and vast surface area to carry large dose of drug 
are considered as main advantages of these systems (346). Drug delivery for cancer treatment 
using metal nanoparticles such as gold nanoparticles are common and shown to be successful (176, 
234). Gold nanoparticles have also been helpful in diagnosing cancer conditions (243). 
 
1.7.1.2 Lipid based 
Lipid based systems – they are composed of chemical compounds possessing both hydrophilic 
and lipophilic properties (amphiphiles), which self-assemble into liquid crystalline phases and can 
be dispersed into nano-sized particles. Hydrophobic drugs can be encapsulated into hydrophobic 
regions and hydrophilic drugs can be incorporated to the hydrophilic part (265). These lipid based 
systems are broadly classified into three types , emulsion based systems (microemulsions, 
nanoemulsions), vascular systems (liposomes, niosomes) and lipid particulate systems 
(liposheres,solid lipid nanoparticles) (285).  
 
1.7.1.3 Polymer based 
Polymer based systems – A polymer is a large molecule that is composed of many repeated 
subunits (236). These biologically active polymers can be merged with drugs and provide 
therapeutic benefits. As they are biodegradable, it improves release and prevent accumulation. 
Thereby, these can modify transport and circulation half-life which allow efficient passive and 
active targeting in delivering therapeutics (190). Some commonly used polymeric material for 
drug delivery are cellulose derivatives, poly (ethylene glycol) PEG, PLA: poly(lactide), poly-e-
caprolactone (PCL),  PLGA: poly (lactide-co-glycolide) and poly (N-vinyl pyrrolidone) PVP (190, 
219). Polymer based drug delivery systems can be broadly divided as hydrogels (hydrophilic 
polymer networks able to trap large amounts of water or biological fluids), micelles, dendrimers, 
polyplexes, or polymer-drug conjugates (190).  
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1.7.1.4 Carbon nanotubes 
Carbon nanotubes (CNT) – These are nano-sized carbon cylinders composed of benzene rings 
capable of drug encapsulation (265).These CNTs are either single-walled CNT; (SWNT) produced 
by rolling up a single layer of graphene sheet or multi-walled CNT; (MWNT) by rolling up many 
layers to form concentric cylinders (33). Functionalized-CNT (f-CNT) are created by linking 
active molecules such as, peptides, proteins, nucleic acids and other therapeutic agents (33). These 
f-CNT have the ability to penetrate into the cells and act as vehicles for the delivery of small drug 
molecules (237). 
 
1.7.1.5 Biological nanoparticles 
Biological nanoparticles – Bovine serum albumin (BSA) is one of the common biological 
material used for generation of nanoparticles in a drug delivery system (73, 252) . Gelatine is 
another material considered as a biological nanoparticle as the amino acid side-chains of the gelatin 
matrix molecule offer multiple modifications, making gelatin nanoparticles a great carrier for drug 
delivery intravenously with few surface modifications (286). 
 
1.7.2 Safety of nanoparticle based delivery systems 
Proper evaluation of the safety of a nanoparticle based drug delivery system is important 
before introducing it as a vehicle. As the field of NP based drug delivery is immense and composed 
of a large number of various materials, it is impossible to make generalized statements about the 
safety of all nanoparticles in general. Several nano-therapeutics are currently approved such as, 
PEGylated (polyethylene glycol bound), liposomal doxorubicin (Doxil®/Caelyx®), albumin-
bound paclitaxel are considered safe with fewer side effects, while other nanoparticles (e.g. 
metallic and carbon-based particles) tend to show more toxic effects in certain conditions (334). 
Therefore, the potential toxicity of a nanoparticle based drug delivery system greatly depends on 
the actual composition of the nanoparticle formulation (73). In safety studies, the physicochemical 
features of a NP and the alterations that it may undergo in different environmental conditions 
should be considered. The size, surface, chemical composition, bioavailability, solubility, 
agglomeration, dissociation and adsorption of environmental substances are factors that may have 
an impact on the ultimate toxicity of the NPs (83). It has been reported that smaller particles 
(approximately 20 nm) were more penetrative into lung tissue with more acute inflammatory 
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reaction than larger ones (less than 200 nm) after intratracheal instillation in mice (230). Certain 
nanoparticles have caused reactive oxygen species generation, oxidative stress, mitochondrial 
perturbation, inflammation, uptake by reticulo-endothelial system, protein 
degradation/denaturation, brain/peripheral nervous system injury, DNA damage, endothelial 
dysfunction/blood clotting, and alternation of cell cycle [reviewed by (328)]. Metallic and carbon 
nanotube based drug delivery systems are believed to be associated with toxicities compared to 
lipid and polymer based systems. The toxicity of CNTs may vary depending on their structural 
characteristics, surface properties and chemical composition (322) However, f-CNTs are proven 
to be non-cytotoxic and preserve the functionality of primary immune cells (82). Pristine CNTs 
are  considered highly toxic, mainly due to their insolubility, therefore it is important to verify the 
solubility of f-CNT in physiological media before used in drug delivery (33)  
When NP based drug delivery systems are considered, scientists and drug developers 
should carefully study several aspects of a NP. In 2004, the US Food and Drug Administration 
(FDA) has introduced the critical path initiative with the intent of safe drug development (335). 
According to this report, three important points to be considered are safety, medical utility, and 
industrialization of a drug. In a NP based drug delivery system, the NP with its drug should be safe 
to be used in humans and animals, effective as a therapeutic agent and able to be produced in a 
large scale (328). A conceptual understanding of biological responses to nanomaterials is needed 
to develop and apply safe nanomaterials in drug delivery in the future (73). 
 
1.7.3 Lipid/surfactant based CpG-ODN delivery 
CpG-ODN is an effective immunostimulant. However, delivery of CpG-ODN alone to 
cells have come across some challenges with suboptimal in vivo stability, toxicity, unfavorable 
pharmacokinetic/ bio distribution characteristics, lack of specificity for target cells and the 
requirement for intracellular uptake. Because of this, the use of lipid-based NPs have been 
suggested to improve ODN stability, enhance ODN delivery to cells, improve cellular uptake by 
target cells and reduce toxicity (333). Many in vivo studies have proven that liposome-entrapped 
drugs and vaccines are better than conventional drugs, mainly in the areas of cancer chemotherapy, 
antimicrobial therapy, vaccines, diagnostic imaging and the treatment of ophthalmic disorders 
(110). As CpG-ODN is negatively charged, use of positively charged cationic lipids can efficiently 
encapsulate and improve the stability of CpG-ODN (207). The immune stimulation of CpG-ODN 
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could be enhanced by encapsulating them in lipid particles for efficient delivery to antigen 
presenting cells (222). There are many studies that have shown these enhanced effects of CpG-
ODN when incorporated in to lipid based delivery systems (114, 189). The enhanced adjuvant 
effect of CpG-ODN was also reported in many studies when incorporated in to a lipid based 
delivery system. One study showed that pigs were protected significantly against pleuropneumonia 
infection when CpG-ODN was used as an adjuvant in a lipid based delivery system (12). Another 
study done in mice showed that liposomes co-encapsulating HCV NS3 (hepatitis C virus non-
structural protein 3) and CpG is a good candidate vaccine which induce strong Th1 immune 
responses against hepatitis C viruses (149). Enhanced adjuvant and anti-tumor activity of CpG-
ODN was presented in another study. They showed that encapsulation in liposomal nanoparticles 
specifically targeted CpG-ODN for uptake by immune cells which resulted in potent innate 
immunity as well as specific immunity (72). Liposomes are also effective delivery vehicles for 
CpG-ODN as an immune adjuvant for T cell independent (TI) antigens (188). A vaccine 
formulated with respiratory syncytial virus fusion protein, CpG-ODN and innate defense regulator 
peptide in polyphosphazene microparticles showed enhanced immune responses and protection in 
mice. The study also revealed that mice received this formulation developed significantly higher 
levels of virus-neutralizing antibodies in the sera and lungs, as well as higher numbers of IFNγ 
secreting cells than mice which received the protein alone (93).  
 
1.7.4 Carbon nanotube based CpG-ODN delivery 
Regardless of the well-known immune properties of CpG-ODN, delivery of CpG-ODN 
faces the challenge of low cellular uptake because of the negative charge of cell membranes, and 
often needs repeated administrations or high doses of ODN (224). DNA could be bound to cationic 
f-CNTs by electrostatic interactions between the phosphate backbone of DNA and the cationic 
functional groups. Therefore, cationic f-CNTs have been considered as an excellent candidate 
carrier to deliver genes (90). Bianco and group reported that cationic carbon nanotubes bound to 
CpG-ODN can enhance their immunostimulatory properties in vitro. They stated that f-CNT 
neutralizes negatively charged CpG-ODN reducing the repulsion by the negatively charged cell 
membrane and therefore, the cellular uptake of CpG-ODN is facilitated. Furthermore, they showed 
that f-CNT did not exert any mitogenic nor any toxic effect on activated or non-activated 
lymphocytes (34).  
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1.7.5 Enhanced CpG-ODN delivery to neonatal chickens 
As described before CpG-ODN has shown promising immunostimulatory properties in 
chickens as an immune modulator and also as a vaccine adjuvant. However, NP based delivery of 
CpG-ODN to chickens have shown enhanced immune properties in several studies. In ovo delivery 
of CpG-ODN formulated with polyphosphazenes (PCPP-Poly [di (carboxylatophenoxy 
phosphazene)] and PCEP-Poly [di (sodium carboxylatoethylphenoxy) phosphazene]) has shown 
enhanced immunoprotective effect against an E. coli infection in neonatal broiler chickens. In the 
same study, birds that received CpG-ODN or CpG-ODN formulated with PCPP or PCEP has 
shown significantly higher survival rate compared to groups that received non-CpG-ODN or saline 
(302).  
 
1.8 Hypothesis 
The economic loss associated with neonatal chicken mortality due to infectious agents is very 
difficult to estimate as losses vary with the type of infectious agents and the degree of virulence. 
In general, if the first week mortality of chicks exceeds 2%, the overall performance of the flock 
will be very poor. Hence, it is important to devise strategies to curtail first week mortality. As 
prophylactic antibiotic use is withdrawn in the Canadian poultry industry, other methods of disease 
prevention and control are being researched. CpG-ODN have gained much attention and shown 
success in immune stimulation and providing protection against infections in many species (18, 
38, 124, 182, 228, 229), including chickens (65, 105, 132). In chickens, immune stimulation is 
mostly required at the time of hatch when they are the most susceptible. Therefore, we hypothesize 
that the in ovo route is an ideal route of  CpG-ODN administration to chicken embryos so that the 
immune system is ready at hatch providing protection against infectious disease related morbidity 
and mortality. In addition, understanding the immune protective mechanisms of CpG-ODN, 
optimizing and extending its bioavailability and duration of action will increase its therapeutic 
value in neonatal chickens.  Furthermore, the effective delivery of CpG-ODN by in ovo route can 
be enhanced by using efficient drug delivery methods.  
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1.9 Objectives 
1. To study the immune mechanisms of in ovo CpG-ODN in neonatal broiler chickens: 
a. Kinetics of cytokine gene expression involved in immune protective effect of CpG-
ODN (multiplex assay for mRNA gene expression) 
b. Cellular mechanisms involved in immune protective effect of CpG-ODN (flo 
cytometry) 
2. Evaluate CpG-ODN induced changes in immune cells in spleen and lung of neonatal 
chicken, and investigate if immune profiles correlate with the CpG-ODN induced 
protection against E. coli infection. 
3. Study immune protective effects and safety of CpG-ODN formulated with CNT or lipid 
based delivery systems for in ovo delivery. 
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PREFACE TO CHAPTER 2 
Immune stimulation in newly hatched chickens has become a main concern in the poultry 
industry. Since the immune system is still developing, young chickens are more susceptible to 
bacterial infections such as E. coli and Salmonella infections (131). CpG-ODN has been studied 
and proved to be an ideal candidate for immune stimulation in chickens (104, 132, 301, 302). 
Moreover, in ovo delivery of CpG-ODN has shown promising results in immune protection in 
neonatal chickens (65, 104, 202). Though several studies have investigated the mechanism of 
action of CpG-ODN as an immune protective agent in chickens (240, 338), detailed studies on 
cellular changes are scarce. In both innate and adaptive immunity, immune cells plays the main 
role in successful pathogen suppression and elimination. APCs like, macrophages and DCs 
identify pathogens via PRR, process and present antigens to T cells. Once lymphocytes are 
stimulated, necessary adaptive immune responses takes place to fight the pathogen (273). As CpG-
ODN act as a PAMP, which can be identified by PRR (TLR9 and TLR21 in chickens) the 
preparation of the immune system can be achieved even without a real pathogen invasion (319). 
Studies have shown the cellular changes caused by CpG-ODN in different species, such as mice 
(119, 174) and humans (116, 307). However, studies on CpG-ODN mechanism in chickens are 
exiguous. CpG-induced intracellular Salmonella Enteritidis bacterial killing was demonstrated in 
a chicken macrophage cell line by Xie et al. 2003 (338). Meanwhile, another group reported similar 
findings in the same macrophage cell line and peripheral blood mononuclear cells (PBMCs). In 
addition they evaluated the ability of CpG-ODN to produce cytokines (IL1β, IFN-γ) in these cells 
(130). In vivo studies on cellular changes in chickens, due to CpG-ODN are not studied extensively 
so far. In the following chapter (Chapter 2) we discuss the cellular changes, cytokines involved 
and expression of cellular markers on immune cells following in ovo CpG-ODN administration to 
chicken embryos in detail. Flow cytometric analysis of macrophage/monocyte cell population, 
their maturation markers and T lymphocyte populations will be described. In addition, cytokine 
gene expression, which was analysed by QuantiGene plex assay will be explained.  
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CHAPTER 2: SYNTHETIC CpG-ODN RAPIDLY ENRICHES IMMUNE 
COMPARTMENTS IN NEONATAL CHICKS TO INDUCE PROTECTIVE IMMUNITY 
AGAINST BACTERIAL INFECTION 
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2.1 Abstract 
CpG-ODN are known to induce innate immunity and protection against bacterial infections. 
Despite recent advances, how CpG-ODN alone protects against bacterial infections remained 
elusive. Here, we report that CpG-ODN regulates the enrichment of immune compartments in 
chickens to orchestrate protective immunity against pathogenic insults. In this study, eighteen-day-
old embryonated eggs were injected with either 50 µg of CpG-ODN or saline (n≈90 per group for 
three experiments). In the first experiment, four days after CpG-ODN treatment, chicks were 
challenged subcutaneously with either 1×104 or 1×105 colony forming units (cfu) of a virulent 
strain of E. coli and mortality was monitored for 8 days. We found significant protection, and 
reduced clinical scores in CpG-ODN treated chicks. To gain insights into mechanisms of 
protection induced by CpG-ODN, first we investigated cytokine expression kinetics elicited by 
CpG-ODN. The expression profiles were examined using QuantiGene Plex 2.0®, which employs 
probes to detect mRNA of multiple target genes in a single assay. The spleen and lung were 
collected from three embryos or chicks per group at 10 time points post-CpG-ODN inoculation. 
Multiplex gene analysis (IL18, IFNα, IFNγ, IL1β, Litaf, IL4, IL6, and IL10) revealed a 
significantly higher expression of pro-inflammatory cytokines following CpG-ODN treatment 
compared to the saline controls. In our study, Litaf stands out in the cytokine profiles of spleen 
and lungs, underscoring its role in CpG-ODN-induced protection. The third experiment was 
designed to examine the effects of CpG-ODN on immune cell populations in various organs. We 
collected spleen, lungs, and thymus from embryos or chicks (n=3 or 4 per group) at 24, 48 and 72 
hours (thymus only collected at 72 hours) after CpG-ODN administration. Flow cytometry analysis 
was conducted to examine the changes in CD4+ and CD8+ T-cell subsets, monocyte/macrophage 
cell populations and their expression of maturation markers (CD40 and CD86). Flow cytometry 
data indicated a significant enrichment of macrophages, CD4+ and CD8+ T-cell subsets in both 
spleen and lungs of CpG-ODN treated embryos and chicks. Macrophages in spleen and lungs 
showed an upregulation of CD40 but not CD86, whereas thymocytes revealed significantly high 
CD4 and CD8 expression. Overall, the present study has demonstrated for the first time that in ovo 
delivery of CpG-ODN provides protection in neonatal chicks against E. coli infection not only by 
eliciting cytokine responses and stimulating immune cells but also through enriching 
immunological niches in spleen and lungs.  
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2.2  Introduction 
CpG-ODNs are short segments of DNA representing a type of PAMP that stimulate 
immune cells and trigger immune responses to infections (61, 115, 158, 198, 233). CpG-ODNs act 
as immunostimulatory agents in many vertebral species including mice (49), human (1, 213, 330), 
fish (151), cattle and sheep (228), and chickens (63, 104, 301). CpG-ODNs are recognized by 
TLR9 and TLR21 in mammals and avians, respectively. Human TLR9 and avian TLR21 are very 
similar in CpG-ODN motif recognition; and both respond to CpG-ODNs containing GTCGTT 
motifs, whereas murine but not human TLR9 recognizes GACGTT motifs (127, 343). Human 
TLR9 and avian TLR21 have similar intracellular localization, signaling cascades, immune 
activation, and cytokine induction (40, 41, 159, 343). Studies reported that CpG-ODNs support 
innate and adaptive immunity by activating immune cells and inducing cytokine secretion (123). 
CpG-ODNs have great promise as vaccine adjuvants and immunotherapeutic agents against 
infectious diseases and cancer (36, 123, 283, 349).  
Our lab has provided the first in vivo evidence for an immunoprotective effect of CpG-
ODN against bacterial infection in chickens (105). We demonstrated protection against E. coli 
infection in chickens administered CpG-ODN via SC or IM (105) or in ovo routes (104). We 
recently reported that intrapulmonary delivery of CpG-ODN micro-droplets could also protect 
neonatal chicks against E. coli septicemia in a dose-dependent manner (106). The 
immunoprotective effect of CpG-ODN in chickens was further supported by the studies 
demonstrating protection against Salmonella Enteritidis infection following CpG-ODN 
administration via intraperitoneal (131) or in ovo (202)  routes. We also demonstrated protective 
effects of CpG-ODN against Salmonella Typhimurium infection (301). The immune protective 
effect of CpG-ODN can further be improved by formulating it with nanoparticles (112, 302, 304). 
CpG-ODN was shown to stimulate strong induction of IL6 and nitric oxide secretion in chicken 
macrophage cell line (HD11 cells) leading to an increased intracellular killing of Salmonella 
Enteritidis in the activated HD11 cells (338). CpG-ODN can activate several signaling pathways 
including protein kinase C (PKC), NF-kappaB and mitogen-activated protein kinases (p38 MAPK 
and MEK1/2) (129). Another study reported a significant increase in the heterophil degranulation 
and oxidative burst following an intraperitoneal administration of CpG-ODN that caused an 
enhanced resistance to Salmonella Enteritidis infection in neonatal chickens (132). The resistance 
to intracellular bacterial infection may be the result of a Th1 biased immune response in chickens 
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that was recently reported to be elicited by CpG-ODN (240). Several recent studies showed 
enhanced expression of cytokines and chemokines in response to CpG-ODN in chickens (66, 304). 
Despite these advances, the mechanisms by which CpG-ODN alone provides protection in 
chickens against bacterial infections are not completely understood. A greater understanding of 
cellular and molecular mechanisms for CpG-ODN induced antimicrobial immunity will help in 
harnessing the full therapeutic potential of CpG-ODNs against diseases. 
In the present study, we investigated immunity induced by in ovo administered CpG-ODN 
including response to E. coli challenge, cytokine kinetics by using QuantiGene Plex (multiplex 
assay for mRNA gene expression), and effects on the immunological niches in spleen and lungs 
using flow cytometry. 
 
2.3 Materials and methods 
2.3.1 Synthetic CpG-ODN  
The sequence of CpG-ODN (class B CpG 2007) used was 5’-
TCGTCGTTGTCGTTTTGTCGTT- 3’. ODNs were produced with a phosphorothioate backbone 
(Operon Biotechnologies, Inc. Huntsville, AL).  
 
2.3.2 Bacteria 
The bacterial strain for challenge was obtained from a field isolate of E. coli from a turkey 
with septicemia as described in previous studies (104, 105). This E. coli was serogroup O2, non-
hemolytic, serum-resistant, produced aerobactin, with a K1 capsule and Type 1 pili. Aliquots of 
bacteria were stored at -80 C in 50% brain heart infusion broth (BHI; Difco, Detroit, MI) 
supplemented with 25% (w/v) glycerol (VWR Scientific, Inc., Montreal, Quebec). Bacteria used 
for challenge were cultured on Columbia sheep blood agar plates for 18-24 hr at 37 C. One colony 
was added to 100 mL of Luria broth in a 250 mL Erlenmeyer flask. The culture was grown at 37 
C for 16 - 18 hr with shaking at 150 rpm. Stationary phase culture contained approximately 1×109 
cfu of bacteria per mL. The cultures were further diluted in sterile saline so the concentration of 
bacteria required for challenge (1×105 or 1×104 cfu/bird) was obtained. Viable bacterial counts 
were determined by plating serial dilutions of the diluted culture in duplicate on Columbia sheep 
blood agar plates, incubating for 18-24 hrs at 37 C; then counting the number of colonies. 
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2.3.3 Chicken embryos 
For all experiments (E. coli challenge study ,gene expression and flow cytometry analysis), 
fertilized hatching eggs were obtained from a commercial broiler breeder operation in 
Saskatchewan, Canada. Eggs were incubated until hatch at the Animal Care Unit (ACU) at the 
Western College of Veterinary Medicine, University of Saskatchewan. This work was approved 
by the University of Saskatchewan’s Animal Research Ethics Board and adhered to the Canadian 
Council on Animal Care guidelines for humane animal use. 
 
2.3.4 Animal model for E. coli challenge 
Hatched chicks were allocated into an animal isolation room at the ACU. An identification 
tag was placed on their neck in order to identify birds that received in ovo CpG-ODN or saline. 
Water and commercial broiler ration were provided ad libitum throughout the trial. The animal 
room was ventilated with filtered, non-recirculated air at a rate of 10–12 changes/hr. In addition, 
air pressure differentials and strict sanitation were maintained in this isolation facility. One day 
post-hatch, the birds received either 1×104 or 1×105 cfu of stationary - phase E. coli, in a total 
volume of 250 μL per bird, by subcutaneous injection in the neck, resulting in E. coli septicemia. 
In this model, E. coli septicemia with airsacculitis, pericarditis, perihepatitis or polyserositis 
develops in 60%–90% of birds that are not protected by treatment intervention. The two different 
doses of E. coli were given to groups of birds to simulate field conditions where all birds are not 
exposed to a consistent dose of E. coli in a barn. Birds were assessed three times daily at the critical 
stage (first four days post challenge) and twice thereafter up to 8 days post challenge. Birds were 
observed for clinical signs and each individual bird was assigned a daily clinical score: 0 = normal; 
0.5 = slightly abnormal appearance, slow to move; 1= depressed, reluctant to move; 1.5 = reluctant 
to move, may take a drink and peck some; 2 = unable to stand or reach food or water; and 3 = 
found dead. Birds that received a clinical score of 2 were humanely euthanatized by cervical 
dislocation. Chicks that were found dead or euthanatized were necropsied immediately. On day 8 
post E. coli challenge, the remaining birds were euthanatized by cervical dislocation. Bacterial 
swabs were taken from the air sacs and cultured on Columbia sheep blood agar using a typical 
method of inoculation and streaking on four quadrants of the plate of medium. A semi-quantitative 
estimate of E. coli isolation was conducted on Columbia sheep blood agar. Growth on these plates 
were recorded on a scale from 0 to 4+, where 0 = no growth; 1+ = growth of bacteria on the area 
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1; 2+ = growth of the bacteria on areas 1 and 2; 3+ = growth of bacteria on areas 1, 2, and 3; and 
4+ = growth of bacteria on areas 1, 2, 3, and 4. 
 
2.3.5 Cells for flow cytometry 
Cell preparation and antibody staining for flow cytometry was done as previously 
described with some modifications (6, 113, 179). Briefly, spleen, lung and thymus tissues were 
collected at 24, 48 and 72 hr post in ovo injection from chicken embryos and processed for cell 
isolation (thymus only at 72 hr). Each spleen was gently pushed through a metal strainer by manual 
pressure to obtain a single cell suspension with ~3 mL of phosphate buffered saline (PBS) and 
collected in a 15 mL centrifuge tube. For lung and thymus, each tissue was manually dissected and 
incubated with ~1 mL of collagenase (1 mg/mL) dissolved in Dulbecco's Modified Eagle Medium 
for 30 min in 37 C. After incubation these tissues were pushed through a metal strainer to obtain a 
single cell suspension and washed twice with PBS. Then all spleen, lung and thymus cells were 
incubated with red blood cell lysis buffer to lyse red blood cells. Following three washes with wash 
buffer (PBS containing 2% fetal bovine serum and 0.1% sodium azide) cells were used for the 
flow cytometry after staining with appropriate antibodies. 
 
2.3.6 Antibodies for flow cytometry 
Monoclonal antibodies against chicken monocyte/ macrophages (mouse anti-chicken 
monocyte/ macrophages KUL01-PE), CD4 (mouse anti-chicken CD4-PE) and CD8 (mouse anti-
chicken CD8α-FITC) were purchased from Southern Biotechnology (Birmingham, Ala, USA). 
Mouse anti-chicken CD40 and mouse anti-chicken CD86 monoclonal antibodies were used as 
primary antibodies (purchased from Bio-Rad, Raleigh, NC, USA). Anti-mouse-FITC IgG antibody 
was used as secondary antibody. Goat anti-mouse IgG, Streptavidin-PerCP/Cy5.5 and Mouse IgG1 
isotype control were purchased from Bio Legend (San Diego, CA, USA). 
 
2.3.7 Experimental design 
2.3.7.1 Delivery of CpG-ODN by the in ovo route 
Embryonated eggs that were 18-days old were injected with 50 µg of synthetic CpG-ODN 
dissolved in sterile pyrogen-free saline, in a total volume of 100µL/egg (n≈90 for all three 
experiments) or 100 µL of sterile saline (n≈90). The air cell side of each egg was cleaned with an 
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alcohol wipe and injections were administered into the amniotic cavity through the air cell using a 
22 gauge, 1 inch hypodermic needle. Following injections, a drop of melted wax was placed on 
the pore created to seal the egg. All eggs were then transferred to the incubator until hatch or taken 
for tissue sample collection. 
 
2.3.7.2 E. coli challenge 
Four days after in ovo injections (day-1 post-hatch), either 1×104 or 1×105 cfu of a virulent 
strain of E. coli was inoculated subcutaneously in the neck in all remaining (after sample collection 
for flow cytometry and gene analysis) hatched birds [bird numbers per group; CpG-ODN 50 µg: 
n = 32; saline: n=36]. Clinical signs, pathology, bacterial isolations from the air sacs, and mortality 
were observed for 8 days following challenge with E. coli. 
 
2.3.7.3 Sample collection.  
For QuantiGene Plex assay- spleen and lung samples from three embryos or newly hatched 
chicks per group were collected at each of 10 time points post CpG-ODN inoculation (0, 3, 6, 12, 
24, 32, 48, 72 hr, day 5 and day 7) into 1.5 mL tubes and flash frozen in dry ice until stored in -80 
C. 
For flow cytometry-three embryos or newly hatched chicks from each group were 
humanely euthanized at 24, 48 and 72 hr post in ovo injections by cervical dislocation and 
necropsied for spleen, lung and thymus tissue collection (thymus only at 72 hr post in ovo 
injections). 
 
2.3.7.4 Gene expression analysis 
The mRNA gene expression of IFNα, IL18, IFNγ, IL1β, Litaf, IL4, IL6 and IL10 cytokine 
genes in the spleen and lung were measured by commercially available probes for avian cytokines 
(Panomics /Affymetrix Inc., Fremont, CA, USA) by QuantiGene Plex 2.0® technique. The genes 
of interest and their accession numbers are listed in Table 2-1.  
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Table 2-1: Genes of interest. (* housekeeping genes- HKGs)  
Gene Gene name Accession number 
IL18 Interleukin 18 NM_204608 
IL4 Interleukin 4 NM_001007079 
IFNα Interferon alpha NM_205427 
IL10 Interleukin 10 NM_001004414 
IFNγ Interferon gamma NM_205149 
IL1β Interleukin 1, beta NM_204524 
Hprt 1* Hypoxanthine-guanine phosphoribosyl transferase 1 NM_204848 
Litaf Lipopolysaccharide-induced TNF factor-alpha factor NM_204267 
Tubb 1* Tubulin, beta 1 NM_205445 
IL6 Interleukin 6 NM_204628 
 
Frozen spleen and lung tissues were processed and tissue homogenates were prepared 
following the manufacturer’s instructions with some modifications. Briefly, 5 mg of tissue was 
excised, manually broken down and added to 300 µL of homogenization solution and 3µL of 
proteinase K. The tissue lysate was digested at 65 C to release the mRNA and centrifuged to 
precipitate the debris. The supernatant of tissue lysates were collected and stored in -80 C if not 
used the same day. The oligonucleotide capture probes for mRNA and label probes were designed 
by the manufacturer as requested. The tissue homogenates were added to a 96-well plate (40 
µL/well) that was pre-loaded with 20 mL of the capture reagent and the respective probe set. After 
overnight hybridization at 54±1 C, hybridizations with bDNA pre-amplifier 2.0, bDNA amplifier 
2.0, biotinylated label probe and finally substrate were subsequently carried out according to the 
manufacturer’s instructions. Luminescence was quantified using a Luminex instrument (Bio-Rad, 
USA). Signals, which is the mean fluorescence intensity (MFI) generated from each bead, are 
proportional to the amount of each mRNA captured on the surface of each generated specific probe 
set. (348). The expressions of these genes were normalized with the gene expression of 
hypoxanthine-guanine phosphoribosyl transferase 1 (Hprt 1) and tubulin beta 1 (Tubb1) genes 
which were used as housekeeping genes.  
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2.3.7.5 Flow cytometry 
The lung and spleen cell populations were stained for the presence of 
monocyte/macrophages, CD4+ and CD8+ T cells. The monocyte/macrophages were further 
analysed for the expression of maturation markers (CD40 and CD86). Briefly, ~5x105 cells were 
incubated with mouse anti-chicken monocyte/macrophage phycoerythrin (PE) antibody at 4 C for 
30 min for detecting APCs. For checking maturation state of monocyte/macrophages, the cells 
from previous step were washed three times and incubated with either mouse anti-chicken CD40 
or CD86 primary antibodies separately at 4 C for 30 min. After three washings with PBS, the cells 
were stained with PerCP/Cy5.5 goat anti-mouse IgG secondary antibody at 4 C for 30 min. 
Another set of ~5x105 cells were also incubated with mouse anti-chicken CD8 (FITC) and CD4 
(PE) together at 4 C for 30 minutes to determined CD4+ and CD8+  T cells.  Lastly, the washed 
cells were suspended in 300 µL buffer in flow tubes and processed for flow cytometric analysis. 
Flow cytometry data were acquired by Epics XL (Beckman Coulter) and FACS Caliber (BD 
Bioscience), and data were analyzed with FlowJo software (Tree Star).  
 
2.3.7.6 Statistical analysis 
Survival pattern, cumulative clinical scores (CCS), bacterial percentages and cell populations 
from flow cytometry analysis were graphed and analyzed with the use of Prism (Prism 5.0, 
GraphPad Software Inc., San Diego, CA) with a significance level of P<0.05. The survival patterns 
were compared using the log-rank test and chi-square statistic. For calculating CCS, the clinical 
score for each bird was summed over the 8 day observation period and the significance of 
differences among groups were tested with Kruskal-Wallis nonparametric analysis of variance. 
Dunnett’s test following ANOVA testing was used to test for significant differences of gene 
expression between the CpG-ODN group and the saline control group at each time point. For 
testing difference of APC percentages, CD4+ and CD8+ expression between groups, we used a 
two way ANOVA followed with Bonferroni post-test and Student-t test with Welch’s correction 
for unequal variance, with a significant difference of P<0.05. 
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2.4 Results 
2.4.1 E. coli challenge 
Survival following E. coli challenge was significantly higher in groups of birds that 
received 50 µg of CpG-ODN compared to the saline control group (P 0.04). (Figure 2-1 A). The 
CCS of chicks following E. coli challenge with either 1×104 or 1x105 cfu of E. coli showed that 
the chicks that received 50 µg CpG-ODN had a significantly lower CCS compared to the saline 
group (P=0.03). (Figure 2-1B). Samples collected from the challenged chicks revealed heavy 
bacterial growth more frequently in samples from chicks in the control group than in the CpG-
ODN group (Figure 2-1C). Moreover, the reduction in the relative risk of mortality following E. 
coli challenge was 46.4% compared to the saline control group. The data of groups which received 
1×104 and 1×105 cfu of E. coli were combined for clarity of presentation and analysis. 
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Figure 2-1: Survival percentages, CCS and bacterial scores. (A) Survival of broiler chickens 
following E. coli challenge. Groups of broiler chicken embryos at day 18 of incubation were 
injected with 50µg of CpG-ODN or saline by the in ovo route (n = 32 CpG-ODN, n= 36 saline 
group). Birds that received CpG-ODN were significantly protected against E. coli infection 
compared to the saline control group (P= 0.04). (B) CCS of broiler chickens following E. coli 
challenge with either 1×104 or 1×105 cfu of E. coli. Groups of birds that received 50 µg CpG-ODN 
CpG-ODN had a significantly lower CCS compared to the saline group, (P=0.03). Bar = mean. 
(C) Heavy bacterial growth was observed more frequently in lesions from birds in the saline group 
than in the CpG-ODN group. The substantial number of ‘0’ or ‘no growth’ of bacteria in both 
groups is a common finding in such experiment.  
 
2.4.2 Gene expression analysis  
The mechanism of action of CpG-ODN in these chicks was also elucidated by measuring 
gene expression patterns of pro-inflammatory (IL1β, IL6, Litaf, IL18), Th1 type (IFNγ, IFNα) and 
Th2 type (IL4, IL10) cytokines in spleen and lungs at several hours post CpG-ODN treatment. 
Fold changes of mRNA levels were 1 or >1 at almost all time points in birds of CpG-ODN treated 
group compared to the saline control group. Levels of gene expression were not consistent nor 
followed a specific pattern over time. However, most significant differences in gene expression 
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occurred in the 32  to 48 hour period after treatment. Normalized gene expression of pro-
inflammatory cytokines (IL18, IL1β and IL6 and Litaf) tended to show a relatively higher level in 
CpG-ODN treated group compared saline treated. The expression of IL1β and IL6 in the lungs of 
chickens was many fold higher compared to spleen at 6 through 48 hours and 12 through 48 hours, 
respectively. IL18 and Litaf expression mainly increased between 12 through 72 hours and 32 
through 72 hours, respectively in both organs. (Figure 2-2). The gene expression levels of Th1 
type cytokines (IFNγ, IFNα) were higher in lungs compared to spleens in CpG-ODN treated birds. 
Similarly, Th2 type cytokine (IL4, IL10) gene expression was higher in lung compared to spleen 
in CpG-ODN treated birds. (Figure 2-3). 
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Figure 2-2: Pro-inflammatory cytokine profiles in lungs and spleen. MFI of each gene was 
normalized to the average of house keeping genes (HKGs - Hprt 1 and Tubb 1), then fold changes 
were calculated against the saline control at each time point and the means were graphed. (Dotted 
line shows a fold change of one, which indicates no change compared to the control group and the 
vertical line and horizontal bar show the standard error of mean-SEM). Dunnett’s test following 
ANOVA testing was used to test for significant differences of gene expression between CpG-ODN 
group and the saline control group at each time point. Asterisks indicate groups that were 
significantly different from control group, * = P<0.05, ** = P<0.01 and *** = P<0.001.  
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Figure 2-3: Interferon and regulatory cytokine profile in lung and spleen. MFI of each gene 
was normalized to the average of HKGs – (Hprt 1 and Tubb 1), then fold changes were calculated 
against the saline control at each time point and the means were graphed. (Dotted line shows a fold 
change of one, which indicates no change compared to the control group and the vertical line and 
horizontal bar show the standard error of mean-SEM). Dunnett’s test following ANOVA testing 
was used to test for significant differences of gene expression between CpG-ODN group and the 
saline control group at each time point. Asterisks indicate groups that were significantly different 
from control group, * = P<0.05 and ** = P<0.01. 
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2.4.3 Flow cytometry analysis 
Flow cytometric analysis of spleen and lung cells isolated from birds of saline control and 
CpG-ODN treated groups showed a marked influence of CpG-ODN on APCs 
(monocyte/macrophage), expression of costimulatory markers on APCs and T lymphocyte 
populations. 
 
2.4.3.1 Antigen presenting cells 
The overall cell number was low at 24 hours post treatment, where the chicken embryos 
were 19 days old. Therefore, we could only obtain and analyse spleen cells at this time point. CpG-
ODN treatment caused a notable increase in the number of APCs (monocyte / macrophage cells) 
and the expression of costimulatory molecules (CD40) in spleen and lungs compared to saline 
treated embryos. The percentage of APCs in CpG-ODN treated embryos in spleen at 24, 48 and 
72 hours post treatment were 5.88, 12.6 and 11.2 %, respectively (Figure 2-4 A, B and C). 
Whereas, lower APC percentages were observed in the saline treated group. A considerably higher 
expression of CD40 costimulatory molecules was present on APCs from CpG-ODN treated 
embryos compared to saline treated embryos and it was indicated by a shift in the MFI to the right 
(Figure 2-4). Even though there was higher expression of CD86 in CpG-ODN group compared to 
the saline group, no significant difference was observed at any of the time points. 
A similar trend was observed in the percentage of APCs in the lungs of CpG-ODN treated 
embryos compared to saline treated embryos at 48 and 72 hours post in ovo injections. The 
percentage of APC in the lungs of CpG-ODN treated embryos at 48 and 72 hours post treatment 
were 1.73 and 1.74% whereas the percentage of APCs in saline treated birds at 48 and 72 hours 
were 0.03 and 0.17 % respectively (Figure 2-5 A and B). CD40 expression was significantly higher 
in APC in lungs of CpG-ODN treated embryos compared to saline and was indicated by a shift in 
the MFI to the right. Similar to the spleen, no increase in the expression of CD86 costimulatory 
molecule was observed in APCs in lungs. 
This striking enrichment of immune cells in the CpG-ODN treated group was noticed at all 
three time points (24, 48 and 72 hours post CpG-ODN inoculation) in both spleen and lung. 
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Figure 2-4: Flow cytometic analysis of spleen cells 24hr (A), 48hr (B) and 72hr (C) post in ovo 
injections (day 19, 20 and 21 embryos). Monocyte/macrophage APC populations were gated based 
on forward and side scatter (left). Histogram panels on right indicate the level of CD86 and CD40 
(costimulatory molecules found on APCs) expression on the APCs. (D) Bar diagram show the 
mean percentages of monocyte/macrophage APCs following in ovo treatment in spleen. vertical 
line and horizontal bar show the standard error of mean SEM, n=3. Two way ANOVA following 
Bonferroni post-test was done to compare means of APC percentages of CpG-ODN received 
groups with saline control. Asterisks indicate significant differeces between the groups, 
***=P<0.001. 
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Figure 2-5: Flow cytometric analysis of lung cells. 48 (A) and 72 hr (B) post in ovo injections 
(day 20 and 21 embryos). Monocyte/macrophage APC populations are gated based on forward 
and side scatter (left). Histogram panels on right indicates the level of CD86 and CD40 
(costimulatory molecules found on APCs) expression on the APCs. (C) Bar diagram show the 
mean percentages of monocyte/macrophage APCs following in ovo treatment in lung. Vertical line 
and horizontal bar show the standard error of mean SEM, n=3. Two way ANOVA following 
Bonferroni post-test was done to compare means of APC percentages of CpG-ODN received 
groups with saline control. Asterisks indicate significant differeces between the groups, 
**=P<0.01.  
 
2.4.3.2 CD8+ and CD4+ T cells 
CD8+ and CD4+ T cell populations were analysed in spleen and lung at 72 hrs post CpG-
ODN injections (21 day old embryos). Both CD8+ and CD4+ cells were markedly increased in 
spleen and lung of CpG-ODN treated birds compared to the saline control. The percentage of CD4 
and CD8 T cells in spleen of CpG-ODN treated embryos were 1.89% and 1.09%, respectively 
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compared to 0.22% CD4+ T cells and 0.23% CD8+ T cells in saline control (Figure 2-6A). 
Similarly, the percentage of CD4+ and CD8+ T cells in lungs of CpG treated embryos were 0.67% 
and 6.01%, respectively compared to 0.43% CD4+ T cells and 0.79% CD8+ T cells in saline 
control (Figure 2-6B). Interestingly, while the percentage of CD4+ T cells was significantly higher 
in CpG-ODN group compared to saline in the spleen (Figure 2-6C), the percentage of CD8+ T cell 
increase was more prominent in lungs than CD4+ T cells. (Figure 2-6D) 
 
Figure 2-6: Flow cytometric analysis of spleen and lung, T cell populations in a day 21 
embryo (72 hours post CpG-ODN /saline injection).  (A) spleen and (B) lung. T lymphocytes 
are gated based on forward and side scatter. CD4+ and CD8+ T-cells were quantified using PE-
labelled mouse anti-chicken CD4 and FITC-labelled mouse anti-chicken CD8 monoclonal 
antibodies. The bar diagrams (C) spleen and (D) lung show the mean percentages of CD4+ T-cells 
and CD8+ T-cells 72hrs following in ovo treatment. Vertical line and horizontal bar show the 
standard error of mean SEM, n=3. Two way ANOVA following Bonferroni post-test was done to 
compare means of T cell percentages of CpG-ODN received groups with saline control. Asterisks 
indicate significant differences between the groups, *= P<0.05, ***=P<0.001. 
 
Moreover, to gain insight whether increase in number of CD4+ or CD8+ is due to increased 
differentiation of CD4+ or CD8+ T cells in thymus we looked at thymus cells. We found that the 
T cell population in thymus was remarkable, where 99% of total thymus cells were CD4+/CD8+ 
double positive at the time of hatch with CpG-ODN treatment. Whereas, in saline control it was 
only 85%. Both CD4+ and CD8+ expression levels were significantly higher with CpG-ODN than 
the saline control group. (Figure 2-7). 
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Figure 2-7: T lymphocytes in thymus.  Flow cytometric analysis of thymus T cell populations 
of the saline control and 50 µg CpG-ODN group (n=3/group) at 72 hours post in ovo injections 
(day 21 embryo). (A) T lymphocytes are gated based on forward and side scatter. CD4+ and CD8+ 
T-cells were quantified using PE-labeled mouse anti-chicken CD4 and FITC-labelled mouse anti-
chicken CD8 monoclonal antibodies. (B) Histogram panels indicate the levels of CD4+ and CD8+ 
expression on the T cells (the MFI shown in blue indicates saline treated group, and in red indicates 
the CpG-ODN treated group). (C) Bar diagrams show the MFI of CD4+ and CD8+ expression. 
Difference of MFI between the two groups were compared using Student-t test with Welch’s 
correction for unequal variance. n=3, * = P<0.05.  
 
2.5 Discussion 
There is strong evidence to suggest that CpG-ODN administration modulates innate and 
adaptive immune responses in chickens enhancing resistance to several bacterial pathogens 
including E. coli (104-106), Salmonella Typhimurium (301), Salmonella Enteritidis (131, 202), 
and  Campylobacter jejuni (305). The immunoprotective effects of CpG-ODN have also been 
reported in mice against Helicobacter pylori (251), Yersinia pestis (136), influenza virus (148), 
and Listeria monocytogenes (143).  These findings suggest that CpG-ODN induces protection in 
several species against a wide range of pathogens. However, how CpG-ODN treatment confers 
protection remains poorly understood. The present study was undertaken to gain a greater 
understanding of the mechanisms of CpG-ODN induced host responses that enhance resistance in 
neonatal chickens to a bacterial pathogen. In this study, we examined how CpG-ODN, delivered 
by in ovo route to18-days old embryonated eggs, protects neonatal chicks, 1-day after the hatch 
(four days after the CpG-ODN treatment), against a virulent strain of E. coli. Consistent with our 
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previous studies (103-106), in the present study, we found that CpG-ODN treated chicks were 
significantly protected against E. coli infection.  
During a pathogenic insult, the host immune response is orchestrated by a complex network 
of cytokines that shape the immune process by regulating cellular communication and function. 
CpG ODN has been shown to elicit superior cytokine responses in chicken immune cells in vitro 
compared to other TLR ligands (lipopolysaccharide or Pam3CSK4) (303). Previous studies have 
suggested that the protection conferred by CpG-ODN is primarily due to an enhanced expression 
of cytokines and chemokines in chickens (66, 304). Therefore, we designed experiments to 
evaluate the effects of CpG-ODN administration on the expression profiles of cytokines involved 
in innate and adaptive immune responses. We examined cytokine expression kinetics of eight 
cytokine genes (IFNα, IL18, IFNγ, IL1β, Litaf, IL4, IL6, and IL10) in spleen and lungs of CpG-
ODN treated and the saline control.  In our study, cytokine expression was measured using 
QuantiGene Plex 2.0® assay technique, a multiplex assay that can simultaneously measure 
multiple cytokine genes in a single well of the assay. We found a substantial upregulation of 
cytokines following CpG-ODN treatment in spleen and lungs. The mRNA levels of all cytokines 
tested here tended to be higher in CpG-ODN treated chickens than in the control group at most 
time points. In agreement with a previous study (14), we observed higher expression of IFNs 
following CpG-ODN injections, and this increase was especially notable in the lungs of chickens. 
IFNs are important cytokines in shaping immune responses against pathogens. IFNα and IFNγ 
have been shown to act synergistically to develop an antiviral state and activate macrophages and 
nitric oxide secretion (274). Like Th1 cytokines (i.e.,IFNs), Th2 cytokine IL4 and regulatory 
cytokine IL 10 were also upregulated following CpG-ODN injections and were also more 
noticeable in lungs. A previous study reported that CpG-ODN induces a Th1 type of response in 
chickens (240). However, in our study, we observed both Th1 and Th2 types of response. This 
finding is also supported by the recent report that demonstrated both Th1 and Th2 types of cytokine 
expression in chickens in response to CpG-ODN treatment (304).  
Accumulating evidence suggests that pro-inflammatory cytokines play a crucial role in 
promoting strong immune response against pathogens. Our findings of an enhanced expression of 
pro-inflammatory cytokines, IL1β, IL6, IL18, and Litaf in lungs and spleen following in ovo 
delivery of CpG-ODN suggests that CpG-ODN promotes inflammatory responses in chickens. 
Our finding is also supported by recent studies showing upregulation of pro-inflammatory 
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cytokines in chickens following CpG-ODN treatment (303, 305). IL1β is well known for its 
induction of IL6 (314) and in T cell proliferation (29, 95, 225). We found that among all the 
cytokines investigated in this study, IL1β was the most upregulated (several fold higher compared 
to control) cytokine following CpG-ODN administration. Protective effect of pro-inflammatory 
cytokines is also evident from the study that demonstrated a strong correlation between pro-
inflammatory cytokine level and the resolution of Salmonella Typhimurium infection in chickens 
(26). In the present study, we observed that CpG-ODN treatment led to a more pronounced effect 
on the cytokine profiles in lungs compared to the spleen, which could suggest that CpG-ODN has 
a superior effect on the mucosal immune system. Our finding is also supported by recent studies 
that demonstrated enhanced expression of pro-inflammatory cytokines in response to CpG-ODN 
in intestinal tissues (304) and reduced intestinal colonization with Campylobacter sp. (305). These 
findings suggest that CpG-ODN treatment conditions the chicken immune system against 
pathogenic invasions at mucosal entry levels and support CpG-ODN as a potent mucosal adjuvant 
(304). Proinflammatory cytokines such as IL1β, TNFα, IL18, and IL6 are rapidly released upon 
TLR activation (226). IL18 can stimulate T-cell proliferation and IFNγ release in chickens (101). 
IL18 has also implicated in stimulating TNFα, IL1β, IL8, and IL6 (227). It is worth mentioning 
that IL18 and Litaf (TNFα)  remained upregulated in both spleen and lungs of hatched chicks for 
72 hours post-CpG-ODN treatment. Importantly, among all the cytokines tested here, Litaf 
remained upregulated for almost all time points studied and in both spleen and lungs. TNFα is a 
multifunctional cytokine that has antitumor, antiviral and antibacterial actions. TNFα induces 
upregulation of CD40 and other costimulatory molecules in macrophages and dendritic cells (287).  
In the present study, there were substantial differences in the magnitude and kinetics of 
cytokine expression between CpG-ODN treated and the saline control. These differences can be 
ascribed to both TLR signaling and cellular composition as well as the number of cells in the 
organs investigated. Proinflammatory cytokines such as IL1β and TNFα orchestrate the secretion 
of chemokines and leukocyte cell-surface adhesion molecules, supporting the rapid recruitment of 
immune cells towards inflammatory area (17, 37, 323). CpG-ODN was shown to enhance cytokine 
gene expression in various immune cells in chickens, including bursal cells (13), macrophages 
(22), splenocytes (295), and thrombocytes (294). Proinflammatory cytokines such as IL1β, TNFα, 
IL18, and IL6 are mainly produced by macrophages when stimulated by bacterial products (315).  
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Therefore, we next investigated the recruitment kinetics, and activation of macrophages in 
the immunological niches in spleen and lungs of CpG-ODN treated and saline controls using flow 
cytometry. Flow cytometry data indicated a significantly enhanced enrichment of macrophages in 
both spleen and lungs of CpG-ODN treated embryo and chicks. The flow cytometry profile of 
saline controls revealed a significantly low number of macrophages in spleen and lungs. It is worth 
mentioning that the lungs’ immunological niches had very low number of macrophages, sentinel 
cells that provide the first line of defense against pathogens.  These data can explain why chicks 
are vulnerable to common bacterial infections in their neonatal life (62), as chicks’ immune 
systems are still not fully mature at the time of hatch. Thus, the present study suggests that in ovo 
delivery of CpG-ODN enriches immunological niches in the immature immune system of the 
chicken embryo so that pathogenic insults can be tolerated more efficiently at hatch. Maturation 
of APCs such as macrophages and dendritic cells involves upregulation of costimulatory 
molecules such as CD40, CD80 and CD86, and the production of cytokines (137). Besides, CD40 
signaling was shown to activate the APCs and facilitate CD8+ T-cell priming (271) to generate 
protective CD8+ cytotoxic T cell (CTL) immunity (201). Therefore, we investigated expression of 
CD86 and CD40 on macrophages in spleen and lungs of CpG-ODN treated or saline controls. 
Interestingly, we found that macrophages in CpG-ODN treated chicks were expressing 
significantly high CD40; however, CD86 was not very different than saline control. This 
interesting observation can be explained by the cytokine profiles in our study. In the present study, 
we found significantly higher expression of Litaf in CpG-ODN group in spleen and lungs for 
several days after treatment. A previous study has reported that TNFα induces upregulation of 
CD40 onto macrophages and dendritic cells (287). Furthermore, it was reported that TNFα 
upregulated CD40 but not CD86 in APCs such as Langerhans cells (32, 267). Thus, prolonged 
expression of Litaf in our study and upregulation of CD40 but not CD86 on macrophages may 
implicate Litaf for this observation, which corroborates previous studies on Langerhans cells (32, 
267).  Thus, we hypothesize that enhanced Litaf in CpG-ODN group could be the reason for 
increased CD40 in our study. However, further studies are needed to understand better TLR21- 
Litaf-CD40 axis in chickens. 
We also examined the T-cell compartment in spleen and lungs of CpG-ODN treated and 
saline controls chicks that hatched 72 hours post-CpG-ODN treatment. Flow cytometry revealed 
significantly high number of both CD4+ T and CD8+ T cells in lungs and spleen of CpG-ODN 
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treated group. These data suggest that CpG-ODN promotes the enrichment of T cell 
immunological niches both in lymphoid (spleen) and non-lymphoid (lungs) organs in chickens. 
The increase in the number of immune cells in spleen and lungs can be due to either enhanced 
recruitment of T cells or increase thymic out (generation of T cells in the thymus) or both. Given 
that in thymus T cells are generated as CD4(+) and CD8(+) double positive cells and after thymic 
selection T cells egress thymus as either CD4+ T cells or CD8+ T cells. Therefore, we harvested 
thymus from CpG-ODN treated and saline control chicks to investigate the expression of CD4 and 
CD8 in thymocytes as an indicator of thymopoiesis. Interestingly, we found significantly high 
expression of both CD4 and CD8 in the thymocytes of CpG-ODN treated group, suggesting a 
potentially increased thymic output following CpG-ODN treatment but requires further studies. 
Above mentioned possibility is also supported by a previous study in mice, which demonstrated 
that CpG-ODN treatment resulted in a systemic antigen-independent expansion of both CD4+ and 
CD8+ T cell subsets and suggested that increase in T cell number was the consequence of reduced 
T cell death in CpG-ODN treated mice (67). Previous studies using transgenic mice reported that 
TNFα is constitutively expressed in the thymus (97) and promotes murine (100) and human (268) 
T cell development. In our study, Litaf expression pattern stands out in the cytokine profiles of 
spleen and lungs. Therefore, we hypothesize that CpG-ODN induced Litaf may have more 
significant roles in enriching immune compartments such as spleen and lungs with various sentinel 
immune cells; consequently, neonatal chicks become better equipped to fight against pathogenic 
insults.  
In conclusion, the present study has demonstrated for the first time that in ovo delivery of 
CpG-ODN provides protection in neonatal chicks against E. coli infection not only by eliciting 
cytokine responses but also through enriching immunological niches in spleen and lungs. 
Furthermore, our data highlight the importance of Litaf in CpG-ODN induced immunoprotective 
mechanisms and suggest that future studies on TLR21- Litaf-mediated immune enrichment axis 
will help in harnessing the full therapeutic potential of CpG-ODNs against diseases. 
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PREFACE TO CHAPTER 3 
 
We have shown the successful use of CpG-ODN as an immune protector against infections 
and as an alternative to antibiotics in neonatal chickens when given by the in ovo route (104, 301). 
In the first manuscript of this thesis, we have described the changes in the immune system of 
neonatal chickens following in ovo CpG-ODN administration. Group that received CpG-ODN 
showed a marked increase in APCs and higher expression of co-stimulatory molecules which 
suggests an effective antigen presentation. Higher T cell populations suggests the effective 
adaptive immune responses against pathogens. Higher levels of cytokine gene expression also 
suggest the stimulation of the immune system. Therefore, our data revealed that CpG-ODN not 
only stimulates immune cells but enriches the immunological niche, making neonatal chicks well 
prepared to tackle pathogenic insults.  
Optimum immune stimulation of the host is needed for better protection against infectious 
pathogens. In order to detect a significant protection, the dose of CpG-ODN given per embryo was 
50 µg or more in most studies (65, 104, 301). We investigated the possibility of achieving the same 
immune protection and immune stimulation with several doses of CpG-ODN lower than this 
amount. The next manuscript in the following chapter (Chapter 3) presents data where we have 
studied the in ovo administration of different doses of CpG-ODN, where the survivability with 
each dose of CpG-ODN following a lethal E. coli challenge was correlated with cellular changes 
with each dose. This manuscript deliver important data about the minimum effective dose which 
can provide sufficient immune protection in neonatal chickens against an E. coli infection. 
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3.1 Abstract 
CpG-ODNs are well known to initiate signaling pathways in cells that elicit innate immunity 
and protection against bacterial infections. We have previously demonstrated the successful use of 
CpG-ODN as an immune protector in neonatal chickens against common bacterial diseases such 
as E. coli and Salmonella  infections. The mechanisms by which CpG-ODN alone protects against 
bacterial infections are not well understood. In this study, we investigated CpG-ODN mediated 
immune cell recruitment in the immunological niches in lymphoid (spleen) and non-lymphoid 
(lungs) organs using various doses of CpG-ODN; and examined whether the immunological 
profiles have any correlation with immunoprotection against E. coli infection. Eighteen-day-old 
embryonated eggs were injected with either 5, 10, 25, 50 µg of CpG-ODN or saline (n=~40 per 
group). On the day of hatch (72 hours after CpG-ODN treatment), we collected spleen and lungs 
(n=3 per group) and examined the recruitment of macrophages/monocytes their expression of 
MHCII and CD40, and the number of CD4+ and CD8+ T-cell subsets in the immunological niches 
in spleen and lungs using flow cytometry. We observed dose-dependent recruitment of immune 
cells, wherein 25 and 50 µg of CpG-ODN induced significant enrichment of immunological niches 
in both spleen and lungs. Four days after the CpG-ODN treatment (1-day after hatch), chicks were 
challenged with a virulent strain of E. coli (1×104 or 1×105 cfu, subcutaneously). Clinical outcome 
and mortality were monitored for 8 days post challenge. We found that both 25 µg and 50 µg of 
CpG-ODN provided significant protection compared to the saline controls against E. coli infection. 
Overall, the present study reports that CpG-ODN induced protection of neonatal chickens against 
pathogenic insults is not only through immune cell stimulation but also via the orchestration of 
immunological niches in chickens. 
 
3.2 Introduction 
Infectious diseases of neonatal poultry are common due to the immaturity of the immune 
system or inadequate sensitization of the immune system to antigens (77). During the first week 
of a bird’s life high mortality associated with bacterial infections, E. coli septicemia in particular 
(118), has devastating impacts on poultry production (342). Antimicrobials are effective in 
controlling bacterial diseases, and thus the prophylactic use of antimicrobials is in common 
practice in the poultry industry (106). This prophylactic use of antibiotics in the poultry industry 
may lead to antibiotic residues in poultry products (46, 117) and emergence of antibiotic-resistant 
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strains of bacteria (108). Hence reduction of antimicrobial use is a priority of the poultry industry, 
and thus the use of category I antibiotics has been discontinued since 2014 (43). The poultry 
industry needs suitable alternatives to antibiotics for controlling diseases in neonatal chickens (15, 
217). 
Innate immunity is the first line of defense against infectious agents. The host needs to 
identify an invading pathogen to mount a rapid immune response. Cells of the innate immune 
system rely on a set of PRR, which can detect specific molecular structures present in pathogens 
known as PAMPs (171). The innate immune cells, like DC, are activated following interaction of 
PRR of DC with PAMP of a pathogen. Such PRR-PAMP interaction initiates cell signaling that 
mounts immune responses, eventually leading to the development of adaptive immunity against 
the invading pathogen. TLRs are the main PRR, which are important in the induction of innate 
immunity (3). Components of pathogens such as lipopeptides, glycerophosphatidylinositol, LPS, 
microbial nucleic acids (dsRNA, ssRNA, unmethylated CpG DNA) and microbial proteins 
(flagellin, profilin) are some of the well-known TLR ligands (PAMPs). Many potential TLR 
agonists have been suggested as immune modulators by different studies (205). Synthetic CpG-
ODNs are recognized by TLR9 and TLR21 in mammals and avian, respectively (127, 172, 343). 
CpG-ODNs initiate immune responses in mice (49), fish (151), cattle and sheep (228), human (1, 
213, 330), and chickens (63, 104, 301). 
In quest of an alternative to antimicrobial agents against bacterial infections, our lab 
pioneered the use of CpG-ODN alone as an immune protective agent against E. coli infection in 
chickens . We demonstrated that CpG-ODN administered through various routes protects chickens 
against E. coli (104-106) and Salmonella Typhimurium infection (301).  The protective effect of 
CpG-ODN was also reported against Salmonella Enteritidis infection by other studies (131, 202). 
It was also demonstrated that CpG-ODN formulation with nanoparticles further improved its 
immunoprotective action (112, 302, 304). Several studies demonstrated enhanced expression of 
cytokines and chemokines following CpG-ODN administration in chickens (66, 304). The 
previous study reported that the resolution of Salmonella Typhimurium infection strongly 
correlated with pro-inflammatory cytokine expression in chickens (26). Despite recent advances, 
the immunoprotective mechanism(s) of CpG-ODN alone against bacterial infections remained 
poorly understood.  
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Proinflammatory cytokines stimulate secretion of chemokines and expression of cell-surface 
leukocyte adhesion molecules and promote rapid recruitment of immune cells in the inflammatory 
area (17, 37, 323). We recently found that intrapulmonary delivery of CpG-ODN initiated the 
infiltration of inflammatory cells, predominantly mononuclear cells with occasional heterophils in 
the pulmonary parenchyma (106). We hypothesize that CpG-ODN-mediated protection may be 
through the regulation of immunological niches in neonatal chickens. Thus, the objective of this 
study was to evaluate the influx of macrophages, CD4+ and CD8+ T-cell subsets in the 
immunological niches such as spleen and lung in chickens, and investigate if immune profiles 
correlate with the CpG-ODN-induced protection against E. coli infection. 
 
3.3 Materials and methods 
3.3.1 Synthetic CpG-ODN 
The sequence of CpG-ODN (class B CpG 2007) used was 5’-
TCGTCGTTGTCGTTTTGTCGTT- 3’. ODNs were produced with a phosphorothioate backbone 
(Operon Biotechnologies, Inc. Huntsville, AL). 
3.3.2 Bacteria  
For the challenge, a field isolate of E. coli from a turkey with septicemia was used. This E. 
coli strain was serogroup O2, non-hemolytic, serum-resistant, produced aerobactin, with a K1 
capsule and Type 1 pili. Aliquots of bacteria were stored at -80 C in 50% brain heart infusion broth 
(BHI; Difco, Detroit, MI) supplemented with 25% (w/v) glycerol (VWR Scientific, Inc., Montreal, 
Quebec). Bacteria used for challenge were cultured on Columbia sheep blood agar plates for 18-
24 hours at 37 C. One colony was added to 100 mL of Luria broth in a 250 mL Erlenmeyer flask. 
The culture was grown at 37 C for 16 - 18 hours with shaking at 150 rpm. Stationary phase culture 
contained approximately 1×109 cfu of bacteria per mL. The cultures were further diluted in sterile 
saline so the concentration of bacteria required for challenge (1×105 or 1×104 cfu in 250 µL/bird) 
was obtained. Viable bacterial counts were determined by plating serial dilutions of the challenge 
culture in duplicate on Columbia sheep blood agar plates, incubating for 18-24 hours at 37 C; then 
counting the number of colonies. 
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3.3.3 Cells for flow cytometry 
Cell preparation and antibody staining for flow cytometry was done as previously 
described with some modifications (6). Spleen and lung tissues were collected at 72 hours post in 
ovo injections from chicken embryos and processed for cell isolation. Briefly, each spleen was 
gently pushed through a metal strainer by manual pressure to obtain a single cell suspension with 
~3mL of PBS and collected to a 15 mL centrifuge tube. For lung, each tissue was manually 
dissected and incubated with ~1ml of collagenase dissolved in Dulbecco's Modified Eagle Medium 
(DMEM) (1 mg/mL) for 30 minutes in 37 C, after incubation these tissues were filtered through a 
metal strainer to obtain a single cell suspension and washed twice with PBS. Spleen, lung and 
thymus cells were then incubated with RBC lysis buffer to lyse red blood cells. Following three 
washes with wash buffer (PBS containing 2% fetal bovine serum and 0.1% sodium azide), cells 
were stained with appropriate antibodies. 
 
3.3.4 Animal model 
This work was approved by the University of Saskatchewan’s Animal Research Ethics 
Board, and adhered to the Canadian Council on Animal Care guidelines for humane animal use. 
Fertilized hatching eggs were obtained from a commercial broiler breeder operation in 
Saskatchewan, Canada. Eggs were incubated at the ACU at the Western College of Veterinary 
Medicine, University of Saskatchewan. Groups of chicks were allocated randomly into animal 
isolation rooms at the ACU. Water and commercial broiler ration were provided ad libitum. Each 
room was ventilated with filtered, non-recirculated air at a rate of 10–12 changes/hr. Air pressure 
differentials and strict sanitation were maintained in this isolation facility. The birds received either 
1×105 or 1×104 cfu of stationary - phase E. coli, in a total volume of 250 μL per bird, by 
subcutaneous injection in the neck, resulting in E. coli septicemia. In this model, E. coli septicemia 
with airsacculitis, pericarditis, or perihepatitis develops in 60%–90% of birds that are not protected 
by treatment intervention. Either 1×104 or 1×105 cfu of E. coli were given to birds in all groups to 
simulate field conditions since all birds in a commercial poultry barn will not be exposed to a 
consistent dose of E. coli (the number of birds that were challenged with the lower and higher dose 
of E. coli were equal in a group).  Birds were evaluated three times daily at the critical stage (first 
3 days post-challenge) then twice daily thereafter for 7 days post challenge. Birds were observed 
for clinical signs and each individual was assigned a daily clinical score: 0 = normal; 0.5 = slightly 
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abnormal appearance, slow to move; 1= depressed, reluctant to move; 1.5 = reluctant to move, 
may take a drink and peck some; 2 = unable to stand or reach food or water; and 3 = found dead. 
Birds that received a clinical score of 2 were humanely euthanatized by cervical dislocation. 
Chicks that were found dead or euthanatized were necropsied immediately. On day 7 post E. coli 
challenge, the remaining birds were euthanatized by cervical dislocation. Bacterial swabs were 
taken from the air sacs and cultured on Columbia sheep blood agar using a typical method of 
inoculation and streaking on four quadrants of the plate of medium.  A semi-quantitative estimate 
of E. coli isolation was conducted on Columbia sheep blood agar. Growth on these plates were 
recorded on a scale from 0 to 4+, where 0 = no growth; 1+ = growth of bacteria on the area 1; 2+ 
= growth of the bacteria on areas 1 and 2; 3+ = growth of bacteria on areas 1, 2, and 3; and 4+ = 
growth of bacteria on areas 1, 2, 3, and 4. 
 
3.1 Experimental design 
3.1.1 Delivery of CpG-ODN by the in ovo route  
Embryonated eggs which had been incubated for 18 days, received either 50, 25, 10 or 5 µg 
of CpG-ODN diluted in sterile pyrogen-free saline, in a total of 100 µL/egg  or 100 µL of sterile 
saline (n=~40/group). Injections were administered by the in ovo route into the amniotic cavity 
through the air cell side of the egg using a 22 gauge, 1 inch hypodermic needle. The volume of the 
injection and the length of the needle were selected to simulate the standard in ovo injection 
technology used in the poultry industry. Following in ovo injection, the injection sites of eggs were 
covered with melted paraffin applied with a wooden applicator and transferred to the hatcher until 
hatch.  
3.1.2 Tissue sample collection for flow cytometry 
Three embryos from each group were humanely euthanized at 72 hours post in ovo injections 
by cervical dislocation and necropsied for tissue collection. Spleen and lung tissues were collected 
in to 1.5 mL micro centrifuge tubes.  
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3.1.3 E. coli challenge 
Four days after in ovo injections (day-1 post-hatch), either 1×104 or 1×105 cfu of a virulent 
strain of E. coli was inoculated subcutaneously in the neck in all remaining birds [bird numbers 
per group; CpG-ODN 5 µg: n = 37; CpG-ODN 10 µg: n=33; CpG-ODN 25 µg: n= 34; CpG-ODN 
50 µg: n=30, saline: n=35]. Clinical signs, pathology, bacterial isolations from the air sacs, and 
mortality were observed for 8 days following challenge with E. coli. 
 
3.1.4 Flow cytometry 
The cell populations of spleen and lungs collected at 72 hours post in ovo injections from 
each group (n=3), were stained for the presence of APC, cellular markers and CD4+ and CD8+ T-
cell subsets. For detecting APCs, CD40 and MHCII molecule one set of spleen and lung cells (~5 
x 105 cells) were incubated with mouse anti-chicken CD40 primary antibody at 4 C for 30 min 
followed by three washing steps and incubated with goat anti-mouse IgG-PerCP/Cy5.5 secondary 
antibody at 4 C for 30 min. After three washes, cells were stained with mouse anti-chicken 
monocyte/macrophage KUL01 (PE) and mouse anti-chicken MHCII (AF 488) antibody together 
at 4 C for 30, subsequently washed three times and suspended in ~300 µL flow cytometric buffer 
for the analysis. 
Another set of spleen and lungs (~5x105 cells) were incubated with anti-chicken CD8 
(FITC) and CD4 (PE) together at 4 C for 30 minutes to determine CD4+ and CD8+  T cells. 
Following three washes these cells were also suspended in ~300 µL flow cytometric buffer in flow 
tubes and processed for flow cytometric analysis. Flow cytometry data were acquired by Epics XL 
(Beckman Coulter) and FACS Caliber (BD Bioscience), and data was analyzed with FlowJo 
software (Tree Star). 
 
3.2 Statistical analysis 
Prism 5.0, GraphPad Software Inc., San Diego, CA was used to analyse and graph survival 
trends, CCS, bacterial percentages and cell populations from flow cytometry analysis, with a 
significance level of P<0.05. The survival patterns and median survival times were compared using 
the log-rank test and chi-square statistic. The reduction of relative risk of mortality of groups of 
birds were calculated using Microsoft excel. The clinical score for each bird was summed over the 
8-day observation period to calculate the CCS and the significance of differences among groups 
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were tested with the use of Kruskal-Wallis nonparametric analysis of variance. For tetsing 
significant differences of the means of immune cell numbers and their maturation marker 
expression between groups, ANOVA testing was done.  Dunnett’s test was used as a post hoc test 
following ANOVA to assess for significant differences between each treatment group compared 
to the saline control group. For testing difference of CD4+ and CD8+ expression between groups, 
we used a two way ANOVA followed with Bonferroni post test and Student-t test with Welch’s 
correction for unequal variance was used, with a significant difference of P<0.05.  
 
3.3 Results 
3.3.1 Flow cytometry  
Flow cytometry analysis of spleen and lungs at 72 hours post in ovo injections (on the day 
of hatch) showed a significant influence of CpG-ODN on immune cell components of birds. 
Results demonstrated a dose-dependent influence of CpG-ODN affecting cell population 
percentages and cell maturation marker expression levels. 
 
3.3.1.1 Antigen presenting cells 
CpG-ODN showed a strong effect on MHCII expressing APC cell population 
(monocyte/macrophages) 72 hours post in ovo injections. The same pattern was observed in both 
spleen and lung where the APC percentage increased with CpG-ODN dose. The highest APC 
percentage was seen with 50 µg of CpG-ODN and lowest with the saline control. However, both 
groups that received 25 µg and 50 µg of CpG-ODN per bird showed significant increase of APCs 
compared to the saline control group (~5 times higher in spleen and ~4 times higher in lung). 
Whereas, CpG-ODN doses that we tested lower than 25 µg (5 µg and 10 µg) did not show a 
significant effect on APC population compared to the control group in spleen (Figure 3-1A, Figure 
3-1B and Figure 3-1C) and lungs (Figure 3-1D, Figure 3-1E and Figure 3-1F). APCs 
(monocyte/macrophages) were further analysed for the expression of maturation markers (CD40 
costimulatory molecule). The CD40 signaling is well known to activate APCs and facilitate T cell 
priming (271) to generate protective CD8+ cytotoxic T cell (CTL) immunity (201).  The mean 
fluorescence intensity (MFI) of CD40 expression on APCs, with each CpG-ODN dose tested are 
shown in histograms. The MFI increased in a dose-dependednt manner and was maximum with 
the 50µg dose in both spleen (Figure 3-1B) and lung (Figure 3-1E). 
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Figure 3-1: Antigen presenting cells of spleen and lung. Flow cytometric analysis of spleen (A 
and B) and lung (D and E) cells at 72 hours post in ovo injections (day 21 embryo) (n=3-4/group). 
Monocyte/macrophage APC populations with MHCII expression were gated. APCs were 
quantified using PE-labelled mouse anti-chicken monocyte/macrophage and AF488-labeled 
mouse MHCII monoclonal antibodies. Histogram panels (B, spleen and E, lung) below indicates 
the level of CD40 expression on the APCs (the MFI is indicated). Black histogram = isotype 
control; blue = saline, and red = CpG-ODN treated. Bar diagrams on right show the means of total 
percentage of MHCII+APC in spleen (C) and lung (F) (vertical line and horizontal bar show the 
standard error of mean SEM), n=3.  Dunnett’s test following ANOVA testing was used to test for 
significant differences between CpG-ODN doses and the saline control group. Asterisks indicate 
groups that were significantly different from control group, (P<0.05) (MFI – mean fluorescence 
intensity). 
 
3.3.1.2 CD4+ and CD8+ cells 
CD4+ cells (T helper cells) and CD8+ (cytotoxic T cells) are the main two types of T 
lymphocytes which play important roles in both humoral and cell mediate immunity. We evaluated 
the effect of CpG-ODN on CD4+ and CD8+ cell populations in spleen and lung in chickens 72 
hours post-CpG-ODN in ovo injections. Both CD4+ and CD8+ cell populations increased after 
CpG-ODN administration in a dose-dependent manner in spleen (Figure 3-2A) and lungs (Figure 
3-2B). Significant increase in CD4+ and CD8+ T cells (Figure 3-2C, spleen; Figure 3-2D, lungs)  
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(as well as total number of T lymphocytes (CD4+ and CD8+ T  combined) in the spleen (Figure 
3-2E) were detected in the group that received 50 µg CpG-ODN and both groups that received 25 
µg and 50 µg in the lungs (Figure 3-2F). 
 
Figure 3-2: T lymphocytes in spleen and lung.  Flow cytometric analysis of spleen and lung T 
cell populations of each group (n=3) at 72 hours post in ovo injections (day-1 hatch). CD4+ and 
CD8+ T-cells were quantified in spleen (A) and lungs (B) using PE-labelled mouse anti-chicken 
CD4 and FITC-labelled mouse anti-chicken CD8 monoclonal antibodies. Bar diagrams show 
CD4+ and CD8+ T cell number in spleen (C) and lungs (D) and the total number of CD4+ T-cells 
and CD8+ T-cells combined (E) spleen and lungs (F). Two way ANOVA following Bonferroni 
post test was done when CD4+ and CD8+ cells were compared in CpG-ODN recived groups with 
saline control. Dunnett’s test following ANOVA testing was used to test for significant differences 
of total T cells between different CpG-ODN doses and the saline control group. Vertical lines and 
horzontal bars show the standard error of mean-SEM. Asterisks indicate groups that were 
significantly different from the control group, *=P<0.05, **=P<0.01 and ***=P<0.001. 
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3.3.2 E. coli challenge 
Survival following E. coli challenge was significantly higher in groups of birds that 
received 25 or 50 µg of CpG-ODN compared to the saline control group (P=0.03 and 0.04 
respectively). (Figure 3-3A). Moreover, the reduction in the relative risk of mortality following E. 
coli challenge was 48.5% and 47.5% respectively in these groups, compared to the saline control 
group indicating that incrdasing the dose beyond 25 µg did not improve survival. This study 
revealed that the level of protection following E. coli challenge is similar in birds that received 25 
and 50 µg of CpG-ODN (Figure 3-3B). Birds that received 10 µg of CpG-ODN tended to have 
higher survival than the control but was not significant (P=0.59). The survival of birds that received 
5µg of CpG-ODN was similar to the saline control group (Figure 3-3A). The data of groups that 
received either 1×104 and 1×105 cfu of E. coli were combined for clarity of presentation and 
analysis. 
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Figure 3-3: Survival pattern and reduction of relative risk of mortality following E. coli 
challenge.(A). Survival of broiler chickens following E. coli challenge. Groups of broiler chicken 
embryos at day 18 of incubation were injected with either 5 ( ), 10 ( ), 25 ( ), 50 µg (
) of CpG-ODN or sterile saline ( ) by the in ovo route and then challenged with either 
1×105 or 1×104 cfu of E. coli three days later, at the day of hatch. Survival graph was plotted based 
on the event of a death in birds following challenge for each day post challenge in each group. (B).  
The reduction of relative risk of mortality compared to the saline control group following E. coli 
challenge. 
 
The CCS for each bird was calculated by summing the daily scores throughout the 7 day 
observation period post E. coli challenge. A significant difference of CCSs were not detected 
between groups. However, a pattern of increasing CCSs were seen.  The lowest CpG-ODN doses 
and saline control. The lowest CCSs were seen in birds that received 50 µg of CpG-ODN while 
the highest CCSs were detected from the saline control group (Figure 3-4 A). Moreover, birds that 
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received CpG-ODN had lower amount of bacteria isolated from air sac swabs compared to birds 
that received saline (Figure 3-4B). Birds that died or were euthanatized either had airsacculitis or 
pericarditis or a combination of airsacculitis together with pericarditis or polyserositis. 
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Figure 3-4: CCS  and bacterial growth following E. coli challenge. 
(A) CCS of broiler chickens following E. coli challenge. Each data point represents the CCS of 
one bird. (bar = mean with SEM). (B) Bar graph show the percentage of birds in each treatment 
group that had each classification of bacterial growth. Bacterial swabs were taken from air sacs.  
Groups that received 50 and 25 µg of CpG-ODN had fewer birds that showed higher levels (3+ 
and 4+) of bacterial growth compared to other groups. 
71 
 
3.4 Discussion 
While many preventive strategies are being implemented to minimize infectious diseases 
in poultry, they may not be sufficient to avert all pathogenic insults. Immune-based methods that 
stimulate the innate immunity against a broad range of pathogens may provide a promising 
solution to disease problems in the poultry industry. CpG-ODN, a TLR agonist, is well known as 
an immune protective agent against bacterial (105, 301), viral (65, 310) and protozoal (63) 
infections in chickens. Furthermore, several studies have shown that CpG-ODN is effective as an 
immunostimulant in both mature and neonatal chickens against E. coli infections (104-106, 112). 
We have previously shown that CpG-ODN delivered through in ovo route, a most desirable and 
economical method of drug delivery in the chicken industry (258),  can be effective in protecting 
neonatal chickens against bacterial diseases such as those caused by E. coli (104, 112) and 
Salmonella Typhimurium (301). The immunoprotective effect of CpG-ODN was also reported by 
other studies against Salmonella Enteritidis (131, 202)  and Campylobacter sp. (304). The 
formulation of CpG-ODN with nanoparticles further improves the immune protective effect (302, 
304). Previous studies suggested that enhanced expression of cytokines and chemokines (66, 304) 
and increased cellular functions, such as the increase in heterophil degranulation and oxidative 
burst (132), play important roles in CpG-ODN-induced protection in chickens. We have recently 
reported an enhanced infiltration of inflammatory cells in the pulmonary parenchyma following 
an intrapulmonary delivery of CpG-ODN in chickens (106). Despite recent progress, the manner 
that CpG-ODN alone confers immunoprotection against bacterial infection remains poorly 
understood.  
The present study was undertaken to investigate CpG-ODN-mediated immune cell 
recruitment in the immunological niches in lymphoid (spleen) and non-lymphoid (lungs) organs 
in chickens, and examine further if the immunological profiles correlate with protection against  
E. coli. infection in chicks. In this study, we administered various doses of CpG-ODN through in 
ovo route (18-days old embryonated eggs),  and harvested spleen and lungs at hatch to investigate 
CpG-ODN dose effect on the immunological profiles. One day after hatch (four days after the 
CpG-ODN treatment) chicks were challenged with a virulent strain of E. coli to test protection 
from disease. Here, we examined the recruitment of macrophages/monocytes, CD4+ and CD8+ T 
cell subsets in the immunological niches in spleen and lungs. APCs, such as 
macrophages/monocytes constitute essential components in the immune system, which process 
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and present antigens,  and initiate activation of effector immune cells. Maturation of APCs such 
as macrophages and dendritic cells involves increased expression of costimulatory molecules such 
as CD80, CD86, and CD40 (137). CD40 signaling on APC results in APC licensing (full 
activation) that facilitates CD8+ T cell priming (271) to orchestrate protective CD8+ cytotoxic T 
cell (CTL) immunity (201).  Therefore, we examined the number of macrophages/monocytes 
present in spleen and lungs as well as the expression of CD40 on these APCs in CpG-ODN treated 
or saline controls.  
Our results showed a CpG-ODN-dose-dependent increase in the number of 
macrophages/monocytes in the immunological niches in both spleen and lungs. Moreover, we also 
observed an increase in CD40 expression with different doses of CpG-ODN. CD40 signaling is 
important for B cell proliferation, differentiation, T cell proliferation, monocyte and dendritic cell 
growth and cytokine production (169). These data suggest that CpG-ODN administration not only 
enriches immune compartments with sentinal cells such as macrophages/monocytes that play 
important roles fighting pathogens (31) , but also activates them for proper maturation leading to 
the expression of a costimulatory molecule, CD40, which is well known for its role in the 
orchestration of immunity against pathogens (7). These findings seen with CpG-ODN such as 
immune cell activation and maturation were comparable to results of many earlier studies in other 
species (119, 214, 259, 293). The significant increase we observed in MHCII-expressing APCs 
with 25 and 50 µg of in ovo CpG-ODN in both lung and spleen could suggest enhanced antigen 
presentation capability for an effective and rapid pathogen clearance in neonatal chicks. Also, we 
observed a dose-dependent increase in CD4+ and CD8+ T cell populations, which play important 
role in humoral and cell-mediated immunity, in spleen and lungs following CpG-ODN 
administration. These findings suggest that the immunological niches in CpG-ODN-treated chicks 
are well equipped with mature APCs with the ability to activate effector immune cells such as 
CD4+ and CD8+ T lymphocytes. 
We next investigated whether the levels of enrichment of immunological niches in spleen 
and lungs by different doses of CpG-ODN have any correlation with immunoprotection against E. 
coli infection. Therefore, we have assessed the clinical protection of neonatal chickens treated with 
various doses of CpG-ODN by challenging them with a virulent strain of E. coli. Here we noted 
that the protection level of chicks that received 10 µg or below CpG-ODN was not different from 
the chicks that received saline. Consistent with our previous studies (103-106), chicks that received 
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25 µg and 50 µg of CpG-ODN were siginificantly protected compared to the saline controls. This 
protection correlates with the changes we detected in immune cell compartments in chickens at 
the time of hatch by different doses of CpG-ODN. We found that 10 µg, but not 5 µg, CpG-ODN 
dose resulted in the increase of immune cells both in spleen and lungs. However, both the 5 µg 
and 10 µg doses were not significantly different than the saline controls in immune profiles and 
protection. In contrast, chicks that received 25 µg and 50 µg of CpG-ODN demonstrated 
significantly enhanced MHCII-expressing APCs, CD40 expression on these APCs and T cell 
populations that correlated with their ability to resist E. coli infection. Overall, our data revealed a 
previously unrecognized phenomenon that CpG-ODN not only stimulates immune cells but 
remarkably enriche the immunological niche, making neonatal chicks well prepared to tackle 
pathogenic insults.  
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PREFACE TO CHAPTER 4 
 
We have discussed the immune modulation and an effective minimum dose of CpG-ODN 
that can induce protective immunity in neonatal chickens when given by in ovo route, in the 
previous manuscripts in this thesis (chapters 2 and 3). However, as the PRR that identify CpG-
ODN (identified as TLR21 in chickens) is located intracellularly, localized in the ER of resting 
cells (41), injected CpG-ODN that reach cells may be destructed along the way. In addition, the 
route of in ovo delivery itself can affect for the loss of CpG-ODN reaching target cells due to 
numerous barriers and nucleases. This directed us in considering methods to improve cellular 
delivery of CpG-ODN.  
Improved cellular delivery of a bioactive substance can be achieved by many proposed 
drug delivery systems. The field of nanoparticle based drug delivery has become very popular over 
the last few decades (256). Lipid based drug delivery systems (333) and carbon nanotube based 
delivery systems (34) have been tested and proved as effective CpG DNA delivery vehicles. Lipid 
based systems are well known for their ability to encapsulate and protect CpG-ODN, enhance 
immune cell targeting and facilitate intracellular uptake (333). Whereas carbon nanotubes are 
distinguished as agents that can facilitate and enhance cellular uptake of CpG-ODN (34).  
The following manuscript in this thesis (chapter 4) present data on two types of lipid and 
carbon nanotube based CpG-ODN formulations given by the in ovo route to broiler chickens. We 
have studied and compared the survivability, bacterial loads, and clinical outcome of these 
neonatal chickens following an E. coli challenge within different groups receiving different 
formulations. Furthermore, this manuscript provide data of the safety aspects of these formulations 
when given to chicken embryos 
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4.1 Abstract 
Unformulated ODN containing CpG motifs are well known agents that stimulate the innate 
immune system of vertebrate species against bacterial, viral and protozoan infections. We have 
previously shown significant protection against E. coli or Salmonella Typhimurium infections in 
neonatal broiler chickens with in ovo delivery of unformulated CpG-ODN. In the present study we 
studied the immunoprotective effects of CpG-ODN, formulated with two types of CNTs or two 
types of lipid-surfactant (LSC) delivery systems against E. coli septicemia and  their safety in 
neonatal broilers. Embryonated eggs which had been incubated for 18 days, received either 50 µg 
of CNT-CpG-ODN, 50 µg of LSC-CpG-ODN, 50 µg of unformulated CpG-ODN or saline. Four 
days after exposure to CpG-ODN (day-1 post-hatch), 1×104 or 1×105 cfu of a virulent strain of E. 
coli was inoculated subcutaneously in the neck. Clinical signs, pathology, bacterial isolations from 
the air sacs, and mortality were observed for eight days following challenge with E. coli. Birds 
that received CpG-ODN formulations had a significantly higher survival rate of 60% to 80% 
following E. coli infection. Whereas, survival rates of birds that received saline was 20% to 30%. 
Bacterial loads and clinical scores were low in groups treated with CNT- or LSC-CpG-ODN 
compared to the groups receiving CpG-ODN or saline. Moreover, any adverse effects were not 
observed in any organs or growth rate of birds that received these formulations. We report for the 
first time that CpG-ODN formulated with CNT and LSC have been demonstrated to have an 
immunoprotective effect against an E. coli infection in neonatal broiler chickens following in ovo 
delivery. 
 
4.2 Introduction 
Immune-based methods are gaining much attention as a means of providing protection against 
diseases in animals, mainly food animal species. Neonatal chickens are highly susceptible to 
infections due to their immature immune systems until several weeks post hatch (77) and many 
other stressors, such as handling and transportation.  E. coli  is one of the main pathogens that 
causes a variety of disease syndromes in poultry including yolk-sac infection, omphalitis, 
respiratory tract infection, septicemia, and cellulitis (107). Although vaccines are effective in  
stimulating the immune system for improved disease protection, they may not be available for all 
disease agents and are not effective when an immediate response is required. The use of antibiotics 
is controversial because residues may persist and it can lead to the emergence of antibiotic-resistant 
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microbes. This may result in food allergies and soil or water contamination via fecal excretion of 
antibiotics in poultry manure applied to the land. Thus, there is pressure to restrict the use of 
antibiotics in agriculture. As a result, category 1 antibiotic use was withdrawn from poultry 
farming in 2014 (43). Hence, these trends point to a need for the development of alternative 
strategies for infectious disease control (9).  
The vertebral innate immune system identifies PAMPs by PRR, inducing immune 
responses which prevent infections (211). Non-vertebral DNA which contains comparatively 
higher amounts of unmethylated CpG dinucleotides than vertebral DNA acts as a PAMP. These 
unmethylated CpG dinucleotides (CpG motifs), are recognized as the molecular pattern that 
contributes to the immunostimulatory activity of non-vertebral DNA (5). TLR9 in mammals, 
which is a PRR, recognize these unmethylated CpG motifs and initiates immunostimulatory 
pathways (5). The context of the unmethylated CpG dinucleotides including specific flanking 
sequences are responsible for the extent of immune stimulation (171). Synthetic preparations of 
oligodeoxyneucleotides containing CpG-ODNs simulating non-vertebral DNA, have shown 
similar immunostimulatory activity (341). This discovery has shown an important preventive 
immunotherapeutic treatment option which stimulates the host’s immune system. Studies have 
revealed the immunostimulatory action of CpG-ODNs in many vertebral species including mice 
(49) fish (151) cattle and sheep (228), and chickens (105, 301). Other than the immunostimulatory 
action, CpG-ODNs are being used as vaccine adjuvants due to the ability to activate antigen 
presenting cells and B cells (162). CpG-ODNs are also used for cancer therapy due to natural killer 
cell and cytotoxic T cell activation (162). Furthermore, CpG-ODNs are being used for anti-allergic 
treatments due to the ability to promote Th1-type immune response and thus suppress Th2 type 
allergic responses (162). The immunoprotective effect of CpG-ODN against several crucial 
diseases such as E. coli (103-105) and Salmonella Typhimurium (301) bacterial infections, 
protozoan diseases caused by Eimeria (63) and viral diseases such as infectious bursal disease 
(324) and infectious bronchitis (65) have been demonstrated in chickens. 
There have been several drawbacks to using CpG-ODN as immunostimulatory molecules 
such as cost, large doses needed for an effective response and intra-cellular location of CpG-ODN 
recognizing PRR which is tough to reach. Drug delivery systems have been considered in order to 
overcome these challenges. Many studies have proven that lipid based and carbon nanotube 
associated delivery systems are able improve the immunostimulatory effect and the uptake of CpG-
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ODN in many species, including mice (20),(72),(333), and pigs (10). However, the use of CpG-
ODN delivery and formulation systems in neonatal chickens have not being investigated in detail. 
The therapeutic value of CpG-ODN can be increased by extending the bioavailability and duration 
of action . Unfortunately, CpG-ODN used in vivo is rapidly eliminated from the circulation due to 
adsorption onto serum proteins and degradation by serum nucleases (197). A possible technique 
for protecting CpG-ODNs from degradation while increasing uptake by cells of the immune 
system involves liposome encapsulation (333) or fusion with biphasic lipid vesicles (10). 
Formulating CpG-ODN with polyphosphazene polymers showed enhanced protection of chickens 
from am E. coli infection (302).  
CNTs exist in two types, single-wall (SWNT) and multi-wall (MWNT). CNTs well studied 
and recognised as multipurpose carriers for drug delivery and diagnostic applications. The organic 
functionalization of CNTs can significantly improve their solubility and biocompatibility profile; 
as a result, their manipulation and integration into biological systems has become possible. 
Functionalised CNTs currently hold strong promise as novel systems for the delivery of drugs, 
antigens and genes (33). Use of CNTs to enhance uptake of CpG-ODN and increase antiglioma 
immunity in mice have been reported (20). To our knowledge, CNTs have not been used for 
formulation of CpG-ODN and delivery in chicken embryos. The goals of this study were to 
determine the safety and immunoprotective effects of two types of CNTs and two types of LSCs 
in delivery systems formulated with CpG-ODN as immunostimulants in neonatal broiler chickens. 
 
4.3 Materials and methods 
 
4.3.1 Bacteria 
A field isolate of E. coli from a turkey with septicemia was used as the challenge strain. 
This E. coli was serogroup O2, nonhemolytic, serum-resistant, produced aerobactin, a K1 capsule, 
and Type 1 pili. Aliquots of bacteria were stored at -70 0C in 50% brain heart infusion broth (BHI; 
Difco, Detroit, MI) supplemented with 25% (w/v) glycerol (VWR Scientific, Inc., Montreal, 
Quebec). Bacteria used for the challenge were cultured on Columbia sheep blood agar plates for 
18-24 hours at 370C. One colony was added to 100 mL of Luria broth in a 250 mL Erlenmeyer 
flask. The culture was grown at 37 C for 16 - 18 hours while shaking at 150 rpm. Stationary phase 
culture contained approximately 1×109 cfu of bacteria per mL. The cultures were further diluted 
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in sterile saline so the concentration of bacteria required for the challenge (1×105 or 1×104 cfu/bird) 
was obtained. Viable bacterial counts were determined by plating serial dilutions of the diluted 
culture in duplicate on Columbia sheep blood agar plates, incubating for 18-24 hours at 370C; then 
counting the number of colonies.  
 
4.3.2 Animal model 
This work was approved by the University of Saskatchewan’s Animal Research Ethics 
Board, and followed the Canadian Council on Animal Care guidelines for humane animal use. 
Hatching eggs were obtained from a commercial broiler breeder operation in Saskatchewan, 
Canada. Eggs were incubated at the ACU at the Western College of Veterinary Medicine, 
University of Saskatchewan. Groups of chicks were allocated randomly into animal isolation 
rooms at the ACU, University of Saskatchewan. Water and commercial broiler ration were 
provided ad libitum. Each room was ventilated with filtered, non-recirculated air at a rate of 10–
12 changes/hr. Air pressure differentials and strict sanitation were maintained in this isolation 
facility. The birds received either 1×105 or 1×104 cfu of stationary - phase E. coli, with a total 
volume of 250 μL per bird, by subcutaneous injection in the neck and resulting in E. coli 
septicemia. In this model, E. coli septicemia with airsacculitis, pericarditis, or perihepatitis 
develops in 60%–90% of birds that are not protected by treatment intervention. Two doses of E. 
coli were given to groups of birds to simulate field conditions since all birds in a commercial 
poultry barn will not be exposed to a consistent dose of E. coli. Birds were evaluated three times 
daily at the critical stage then twice thereafter for seven days post challenge. Birds were observed 
for clinical signs, and each individual was assigned a daily clinical score as following,: 0 = normal; 
0.5 = slow to move and slight abnormal appearance; 1= depressed and reluctant to move; 1.5 = 
reluctant to move, may take a drink and peck some feed; 2 = unable to stand or reach food or water; 
and 3 = found dead. Birds with a clinical score of two were euthanatized by cervical dislocation. 
Chicks that were found dead or euthanatized were necropsied immediately. On day seven post E. 
coli challenge, all remaining birds were euthanatized by cervical dislocation. Then, bacterial swabs 
were taken from the air sacs and cultured on Columbia sheep blood agar using a typical method of 
inoculation and streaking on four quadrants of the plate of medium. A semi-quantitative estimate 
of E. coli isolation was conducted on Columbia sheep blood agar. Growth on these plates were 
recorded on a scale from 0 to 4+, where 0 = no growth; 1+ = growth of bacteria on the area 1; 2+ 
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= growth of the bacteria on areas 1 and 2; 3+ = growth of bacteria on areas 1, 2, and 3; and 4+ = 
growth of bacteria on areas 1, 2, 3, and 4. (24). 
 
4.3.3 Synthetic CpG-ODN and CpG-ODN formulation 
The sequence of CpG ODN  (CpG 2007) used was 5’-TCGTCGTTGTCGTTTTGTCGTT-
3’.and non CpG-ODN was 5’-TGCTGCTTGTGCTTTTGTGCTT-3’.ODNs were produced with a 
phosphorothioate backbone (Operon Biotechnologies, Inc. Huntsville, AL). CpG-ODN 
formulations were prepared either with SWNTs or LSCs at the School of Pharmacy, University of 
Waterloo, Canada. Synthetic CpG-ODNs were diluted in sterile, pyrogen-free saline or 
formulation substrates and administered in a 100 µL volume by the in ovo route into the amniotic 
cavity through the air cell of the egg using a 22 gauge, 1 inch needle. The volume of the injection 
and the length of the needle were selected to simulate the in ovo injection technology used in the 
poultry industry. 
 
4.3.3.1 CNT formulations 
SWNT #1 CpG-ODN was prepared using 0.1 mg/mL HiPco SWNTs (Unidym, Inc., 
Sunnyvale, CA) and 0.5 mg/mL CpG-ODN aqueous solution. SWNT #2 CpG-ODN contained 0.1 
mg/mL Puretubes SWNTs (NanoIntegris, Inc., Menlo Park, CA) and 0.5 mg/mL CpG-ODN 
aqueous solution. Both CNT formulations were prepared in glass vials and bath sonicated for 5 
hours at temperatures not exceeding 40 C. Final doses contained 10 μg SWNT and 50 μg CpG-
ODN per 100 μL. 
 
4.3.3.2 Lipid surfactant formulations 
LSC-CpG-ODN (LSC # 1-CpG-ODN) formulations were made up of two phases: an 
aqueous phase (AP;1.1 mg/mL gemini surfactant 12-7NCH3-12 [synthesized in house] and 
0.5mg/mL CpG-ODN dissolved in sterile water for injection (WfI) [Fisher Scientific, Toronto, 
ON, Canada] and a lipid phase (LP; soya phosphatidylcholine, 200 mg/mL (Phospholipon 90H, 
Nattermann Phospholipids GmbH, Koln, Germany], cholesterol, 20 mg/mL[Croda, Vaughan, ON, 
Canada], propylene glycol, 400 mg/mL [Spectrum Chemicals, Gardena, CA]). In a glass vial, all 
of the LP ingredients were weighed out and melted in a 70 C water bath until clear. The premixed, 
prewarmed (to 40 C) AP was added to the LP and incorporated by intermittent vortexing/heating 
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until a homogenous formulation formed. This final mixture was then sonicated in a cup-horn 
Sonicator 4000 (Misonix, Qsonica, LLC, Newtown, CT) on amplitude 11 for 30 min.  
Gemini surfactant-CpG-ODN complexes (LSC # 2-CpG-ODN) were prepared by dissolving 0.5 
mg/mL CpG-ODN in 1.25 mg/mL gemini surfactant 12-3-12 (synthesized in house) in WfI. The 
mixture was bath sonicated for 3 hours at temperatures not exceeding 40 C. 
 
4.3.4 Experimental design 
 
4.3.4.1 Delivery of CpG-ODN formulations by the in ovo route 
The objective of this experiment was to enhance the immunoprotective effects of CpG-
ODN by formulating with SWNTs or LSC in neonatal birds. Eighteen day old embryonated eggs, 
divided to four groups were injected with either 50 µg of CpG-ODN formulated with SWNT 
(SWNT # 1 CpG-ODN), LSC-CpG-ODN (LSC # 1- CpG), unformulated CpG-ODN or saline in 
a total volume of 100 µL/embryo by the in ovo route to the amniotic cavity . Forty embryonating 
eggs were randomly allocated into each of the four groups. After hatching, the groups of birds 
were inoculated on day 1 of age (which was approximately 24 h following hatch) with 1×105 or 
1×104 cfu of stationary phase E. coli by the subcutaneous route in the neck. Half of each group 
(n=20) were inoculated with 1x105 cfu of E. coli and the remaining birds (n=20) were inoculated 
with 1x104 cfu of E. coli. Birds were examined daily for eight days for clinical signs following E. 
coli challenge. Bacterial swabs from air sacs were collected from all dead and euthanized birds 
during the clinical evaluation period, and at the termination of the experiment and cultured. 
The second part of the objective was to study the immunoprotective effect of CpG-ODN 
formulated with two other delivery systems: SWNT (SWNT # 2 CpG-ODN) and LSC # 2-CpG-
ODN. In ovo delivery of formulations, E. coli challenge experiments, ensuing clinical evaluation, 
mortality and bacterial isolations were performed as stated above. In this trial the group sizes were 
SWNT #2-CpG-ODN: n = 33; LSC # 2-CpG-ODN: n = 40; CpG-ODN: n = 26; and saline n = 40. 
A group of 25 birds was maintained with no E. coli challenge for each experiment as the viability 
control of the broiler chicks. 
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4.3.4.2 Safety of CpG-ODN formulated with CNT or LSC 
The third objective of this project was to study the safety and toxicity of these CpG-ODN 
formulations in neonatal broiler chickens until 9 or 42 days post-hatch while being conducted in 
two separate experiments. In the first experiment, four groups of birds (n=18 for each group) were 
injected with SWNT#1-CpG-ODN , LSC # 1-CpG-ODN, CpG-ODN or saline by the in ovo route 
as described above, but were not challenged with E. coli. Birds were examined daily for any 
clinical signs and mortality.For histopathological examination, tissue sections were collected from 
three embryonated eggs or birds that were randomly selected and euthanized from each group at 
six different time points. Tissues harvested were, the gastrointestinal tract (crop, esophagus, 
proventriculus, gizzard, duodenum, jejunum, ileum, and ceca), kidneys, lungs, liver, muscle, 
trachea and lymphoid organs (spleen, bursa, and thymus) at 19, 20 and 21 days of incubation and 
at 3, 6 and 9 days post-hatch. Upon collection, tissue sections were fixed in 10% neutral buffered 
formalin, embedded in paraffin, sectioned at 5μm thickness and stained with hematoxylin and 
eosin.  
In the second experiment, 10 groups of birds (n= 35 for each group) were injected with 
SWNT#1-CpG-ODN ,SWNT #1-non CpG-ODN, LSC # 1-CpG-ODN, LSC # 1-non CpG-ODN, 
SWNT#2-CpG-ODN ,SWNT #2-non CpG-ODN, LSC # 2-CpG-ODN, LSC # 2-non CpG-ODN , 
CpG-ODN or saline by the in ovo route as described earlier. These birds were not challenged with 
E. coli and were observed daily for any clinical signs or mortality up to 42 days post hatch. Tissue 
sections were collected as in the first experiment from the above mentioned organs at the day of 
hatch and at days 7, 14, 28 and 42 post-hatch for histopathology. At each time point, three birds 
were randomly selected from each group and euthanized for sample collection. Tissue sections 
were processed for histopathology as above. Bursal weight to body weight ratio (BBW) is a good 
indicator of growth of birds and the reflection of the immune function of growing birds (19). At 
day 42 post-hatch, following euthanasia, BBW was obtained in addition to tissue sample collection 
for histopathology.  
 
4.4 Statistical analysis 
Survival and other data were analyzed with the use of Prism (Prism 5.0, GraphPad Software 
Inc., San Diego, CA) and Statistix7 (Analytical Software, Tallahassee, FL) with a significance 
level of P<0.05. The survival patterns and median survival times were compared using the log-
83 
 
rank test and chi-square statistic. The relative risk of mortality for control subjects was calculated 
using proportional hazards regression. The clinical score for each bird was summed over the 8-day 
observation period and the significance of differences among groups and comparison of BBW 
between groups were tested with the use of Kruskal-Wallis nonparametric analysis of variance.  
The homogeneity of distribution of bacterial scores was tested using chi-square statistics.  
 
4.5 Results 
 
4.5.1 Delivery of CpG-ODN formulations by the in ovo route 
No mortality was reported from the unchallenged viability control birds. The groups of 
birds that received CpG-ODN either alone or in any formulation experienced about half of the 
relative risk of mortality as the birds that received saline (0.48; P=0.0020 in the first trial and 0.51; 
P=0.0044 in the second trial). This immunomodulation occurred in groups challenged with either 
1×104 or 1×105 cfu of E. coli, and the data were combined for clarity of presentation and analysis 
because there was no significant difference in group mortality between low- and high-challenge 
doses. 
Birds in the first trial that received either CpG-ODN formulated with SWNT no. 1 or LSC 
no. 1 (>75% survival) experienced one third (32%, P<0.001) the relative risk of mortality 
following a lethal dose of E. coli compared to CpG-ODN alone and saline control groups (30% 
survival;( Figure 4-1A). The groups that received formulations with no CpG-ODN were not 
protected against E. coli challenge (P>0.05). The CCS was significantly lower in birds that 
received CpG-ODN formulated with SWNT no. 1 or LSC no. 1 compared to birds that received 
either CpG-ODN alone or saline (P < 0.05; Figure 4-1B). Moreover, birds that received CpG-ODN 
formulated with either SWNT no. 1 or LSC no. 1 had a significantly greater proportion of lower 
bacterial loads compared to birds that received CpG-ODN alone or saline (P<0.005; Figure 4-1C). 
Birds that died or were euthanatized either had airsacculitis or pericarditis or a combination of 
airsacculitis together with pericarditis or polyserositis.  
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Figure 4-1: Experiment 1 results (survival percentages, CCS and bacterial scores).    (A) 
Survival of broiler chickens following E. coli challenge. Groups of broiler chicken embryos at day 
18 of incubation were injected with CpG-ODN or non CpG-ODN formulated with SWNT # 1 or 
LSC # 1, CpG-ODN alone or saline by the in ovo route (n = 40 per group). 50% of birds in each 
group (n = 20) were SC inoculated with 1×104 E. coli and the remaining 50% of birds (n = 20) 
were SC inoculated with 1×10 5 cfu of E. coli at 1 day post-hatch which was approximately 24 
hours following hatch.  Groups of birds that received SWNT # 1 CpG-ODN or LSC # 1-CpG-
ODN were significantly protected against E. coli infection compared to the control group 
(P<0.0001). (B) CCS of broiler chickens following E. coli challenge. CCS of neonatal broiler 
chickens following challenge with 1×104 (n = 20) or 1×105 (n = 20) cfu of E. coli. Groups of birds 
that received 50 µg CpG-ODN formulated as SWNT # 1-CpG-ODN, or LSC #1-CpG-ODN had a 
significantly lower CCS (P<0.05) compared to the unformulated CpG-ODN or saline groups. (Bar 
= median). (C) Bars show the number of birds in each treatment group that had each classification 
of bacterial growth. Bacterial swabs were taken from air sacs.  Groups that received formulated 
CpG-ODN had fewer birds that showed higher levels of bacterial growth. 
 
In the second trial, egg hatch was incomplete at the time of E. coli challenge; hence some 
groups had a reduced number of birds (SWNT no. 2 CpG-ODN, n = 33; SWNT no. 2 non-CpG-
ODN, n = 32; LSC no. 2 CpG-ODN, n = 40; LSC no. 2 non-CpG-ODN, n = 36; CpG-ODN, n =26; 
and saline, n=40). Birds that received CpG-ODN formulated with SWNT no. 2 or LSC no. 2 
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experienced significantly lower risk of mortality (57%, P=0.0149) compared to the birds that 
received CpG-ODN alone or saline (Figure 4-2A). The groups that received formulations with no 
CpG-ODN were not protected against E. coli challenge (P>0.05). The CCS was significantly 
different among groups (P=0.016), and there were two sets of groups between which the CCS was 
significantly different (P< 0.05), as shown in (Figure 4-2B) (SWNT no. 2 CpG-ODN or LSC no. 
2 CpG-ODN vs. CpG-ODN or saline). Additionally, birds that received various treatments had 
significantly different bacterial loads (overall chi-square = 30.94; P=0.002), and more of the birds 
that received CpG-ODN alone or saline had the higher levels of bacteria (Figure 4-2C) 
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Figure 4-2: Experiment 2 results (survival percentages, CCS and bacterial scores).  (A) 
Survival of broiler chickens following E. coli challenge. Groups of broiler chicken embryos at day 
18 of incubation were injected with CpG-ODN and non CpG-ODN formulated with SWNT # 2 or 
LSC # 2, CpG-ODN alone or saline by the in ovo route (n = ~40 per group). Groups of birds that 
received - SWNT # 2 CpG-ODN or LSC # 2- CpG-ODN were significantly protected against E. 
coli infection compared to the saline control group and control SWNT #2 non CpG-ODN group 
(P<0.0001). The group that received unformulated CpG-ODN tended to have increased survival, 
but survival was not statistically significant (P=0.0573). (B) CCS of broiler chickens following E. 
coli challenge. CCS of neonatal broiler chickens following challenge with 1×104 (n = 20) or 1×105 
(n = 20) cfu of E. coli. Groups of birds that received 50 µg CpG-ODN formulated as SWNT # 2-
CpG-ODN, or LSC # 2 CpG-ODN had a significantly lower CCS compared to the unformulated 
CpG-ODN or saline group. [Bird Numbers per group; SWNT #2-CpG-ODN: n = 33; SWNT #2 
non CpG-ODN: n = 32; LSC # 2-CpG-ODN: n = 40; LSC # 2 non CpG-ODN: n = 36; CpG-ODN: 
n = 26; and Saline n = 40] (Bar = median). (C) Heavy bacterial growth was observed more 
frequently in lesions from birds in the control group than in the groups treated with SWNT # 2-
CpG-ODN, LSC # 2 CpG-ODN or unformulated CpG-ODN. 
  
4.5.2 Safety of CpG-ODN formulated with CNT or LSC 
No mortality or clinical signs were detected in any of the embryos or birds following 
administration of CpG-ODN formulations throughout day 9 post-hatch in the first safety 
experiment. No histopathological lesions were diagnosed in any of the organs at any of the time 
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points of embryos or birds throughout day 9 post-hatch in groups that received any CpG-ODN 
formulation, CpG-ODN or saline. 
In the second safety experiment,  no histopathological lesions were observed at any of the 
time points throughout day 42 post-hatch in groups that received CpG-ODN formulations, 
formulation controls (SWNT # 1 non-CpG-ODN, LSC non-CpG-ODN, SWNT # 2 non-CpG-
ODN and surfactant non-CpG-ODN), CpG-ODN or saline. The expected mortality or euthanasia 
of birds due to leg problems (i.e vulgar and varus deformity), sudden death syndrome, ascites and 
right ventricular failure was not significantly different among groups (P>0.05). There was no 
significant difference of the BBW ratio among groups treated with CpG-ODN formulations and 
control groups (P>0.05, Figure 4-3). 
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Figure 4-3:  BBW of birds at 42 days of age.  There was no significant difference between the 
BBW in groups treated with CpG-ODN formulations or control groups (bar = median). 
 
4.6 Discussion 
Immune-stimulatory measures that provide protection against infectious diseases have 
gained great attention at present. They are well known to stimulate the host’s immune system and 
prepare the host to fight pathogenic microbes. Disease prevention by prophylactic measures like 
immune stimulation is favoured compared to the use of therapeutic agents like antibiotics which 
may lead to concerns about residues in edible products, particularly in the food-animal industry. 
Over the years, the use of antibiotics in the food-animal industry has resulted in the emergence of 
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resistant strains of bacteria and the possibility of drug residues in meat products. For these reasons, 
novel immune-stimulants are proposed and investigated as alternative, desirable ways to prevent 
disease in these species. CpG-ODN has been used as an immunostimulant in many species, 
including chickens (49, 105, 151, 228, 264). Previously, we have demonstrated that CpG-ODN is 
an effective immunostimulant in chickens and appeared to have its effectiveness for six days (105) 
following administration. Moreover, we were able to increase the effectiveness of CpG-ODN by 
formulating with polyphosphazenes (302). In the present study; we demonstrated a significant 
health promoting effect of CpG-ODN formulated with CNT or LSC. CpG-ODN formulations 
significantly increase survival, reduce clinical signs and decrease the bacterial load in birds 
challenged with E. coli.   
E. coli or Salmonella septicemia is common in the neonatal period of broiler chickens and 
causes significant mortality and production losses (301). Furthermore, if broiler flocks experience 
mortality greater than 2% in the first week of life, the overall performance of the flock becomes 
very poor due to chronic infections, poor weight gain and uneven birds in the flock (160). It is 
essential to maintain good health during the first week of broiler chicken growth as it will provide 
better performance and profitability at the time of production (77). Currently, in the broiler chicken 
industry, birds can reach a 2 kilogram body weight by 30-35 days post-hatch (253). Thus, in ovo 
delivery of CpG-ODN formulations either with CNT or lipid formulations (LSC) may provide 
effective immunostimulation and may be a better alternative to antibiotics. Likewise, in ovo 
delivery of vaccines is common practice in the broiler chicken industry. Hence, the delivery of 
CpG-ODN formulations is practically feasible. We have previously demonstrated that in ovo 
delivery of unformulated CpG-ODN are effective against E. coli (105) or Salmonella 
Typhimurium (301) septicemia in neonatal broilers, and here we demonstrate a significant 
potentiation of CpG-ODN with CNT or lipid delivery systems in chicken embryos. Moreover, 
CpG-ODN formulations significantly reduce the bacterial load in birds infected with E. coli, and 
suggest that CpG-ODNs may be able to reduce the bacterial load in birds in commercial 
production. We cannot use our animal model of E. coli to validate this possibility since it causes 
very high (between 60-80%) mortality following challenge. 
Even though the potential of using CNTs in drug delivery are widely demonstrated, studies 
have also shown that these particles can potentially cause adverse effects because of their small 
size and extreme aspect ratio (89). However, controversy surrounds the interpretation ascribed to 
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CNT toxicity data. The toxicity reported has found to be related to many properties of the CNT 
material, such as their structure (SWNT vs. MWNT), length and aspect ratio, surface area, degree 
of aggregation, extent of oxidation, surface topology, bound functional group(s), and method of 
manufacturing which can leave catalyst residues and result in impurities. Toxicity of CNTs is also 
related to their concentration and the dose to which cells or organisms are exposed (90). Broiler 
chicken embryos are a well suited model to study toxicity of CNT hence we are able to study 
embryo mortality, hatchability, and clinical signs during a life span of the broiler chicken. In 
addition, all organs can be studied for histopathology to identify any morphological changes. We 
did not see embryo mortality, decreased hatchability, clinical signs or any evidence of alteration 
of the morphology of any internal organs that we studied during day 18 of incubation throughout 
day 42 post-hatch. The bursa of Fabricius is an organ which reflects the immune system and overall 
health of a chicken. Therefore, bursal size is a biological indicator of how well the health of a flock 
is managed and protected from disease. Therefore the BBW is a good indicator of the health status 
of broiler chickens. The BBW ratio was not significantly different among groups of birds treated 
with CpG-ODN formulations or control groups hence, CpG-ODN formulated with CNT or LSC 
did not affect the growth of birds and their immune system. Furthermore, lipid based delivery 
systems, have previously proven to be safe and effective for delivering CpG ODN in many species 
of animals (10, 11).  
In conclusion, CpG-ODN formulated with CNT or lipid surfactant vesicles was observed 
to synergistically enhance the immunoprotective efficiency against E. coli infections in neonatal 
broiler chickens. A large-scale field study will eventually determine the utility of CpG-ODN in 
the broiler chicken industry. It is very encouraging to note that CpG-ODN formulations with CNT 
did not cause adverse reactions in chicken embryos or neonatal broiler chickens. To our 
knowledge, this is the first time that in ovo delivery of CpG-ODN formulated with CNT or lipid-
surfactant delivery systems have shown protection against a lethal bacterial infection in broiler 
chickens.     
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CHAPTER 5: DISCUSSION AND CONCLUSIONS 
The global poultry production was 111,000 thousand metric tons in 2015 and world poultry 
production is projected to increase by 24% over the next decades, reaching 131,255 thousand 
metric tons in 2025 (246). Canada produced chicken products worth $2.5 billion in 2016 (4).  
Although global poultry production increases at a significant rate there are few diseases causing 
significant impact on its growth. Among diseases of the broiler chicken industry, yolk sac 
infections due to bacterial infections in neonatal broiler chickens is a major problem in any  poultry 
producing country. Immaturity of the immune system and stressors associated with handling and 
transport at the time of hatch can make neonatal broiler chickens susceptible to bacterial pathogens 
that could originate from the enviroment. The poultry industry has been using antibiotics as 
preventive measure to reduce these bacterial infections in neonatal chickens but this practice has 
been reducing in many countries due to emergence of antimicrobial resistant bacteria.  In 2014, 
the Canadian poultry industry voluntarily  withdrew the use of category I antibiotics (43). Because 
of these reasons, alternatives to antibiotics and immunotherapeutic agents were received a great 
interest. Among them, CpG-ODN or synthetic CpG motifs have demonstrated immunostimulatory 
properties against patogens. CpG-ODN has shown its effective immune stimulation in chickens 
against many bacterial (104, 105, 301), viral (65, 310) and protozoal (63) infections. However, the 
mechanism of CpG-ODN induced immunoprotection remains poorly understood in chickens. The 
objective of this study was to investigate immune mechanisms at cellular and cytokine gene 
expression levels following in ovo delivery of CpG-ODN as an immune stimulator in broiler 
chicken embryos. We have demonstrated cytokine gene expression and T-cell activation following 
in ovo CpG-ODN administration and effect of CpG-ODN on its dose against E. coli infection. We 
have also demonstrated formulation of CpG-ODN with CNTs and and liposomes to enhance 
immunoprotive efficacy of CpG-ODN against bacterial septicemia. 
The innate immune system plays an important role in identifying and fighting pathogens 
leading to effective adaptive immunity that protect the host against infection (145). In the second 
chapter, we demonstrated increased expression of key immunomodulatory cytokines and their role 
associated with CpG-ODN induced immunoprotection in neonatal chickens against bacterial 
infections. We selected the spleen and lung as organs of interest to assess cytokine gene expression 
and cellular changes. Cytokines play a significant role in inflammation and immune modulation. 
We showed that all cytokines that we evaluated were upregulated than the control group at most 
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time points in both organs. Not only Th1 (IFNs) cytokines but IL4, a Th2 cytokine and IL10 which 
is a regulatory cytokine was upregulated upon CpG-ODN administration. Although we have 
previously shown that CpG-ODN promote Th1 type immunity in chickens (240), our current study 
showed both Th1 and Th2 type immune responses following CpG-ODN administration as shown 
in a recent study in chickens agaist Campylobacter colonization in the intestine (304). The data 
from our study can also be used in designing CpG-ODN as a vaccine adjuvant for poultry 
vaccinest. Furthermore, the upregulation of pro-inflammatory cytokines (IL1β, IL6, IL18, and 
Litaf) in both spleen and lung shows that CpG-ODN induce an proinflammatory response, which 
may contribute to fight against bacterial infections.We also noted a distinct CpG-ODN induced 
pro-inflammatory cytokine gene upregulation in lung compared to the spleen, suggesting enhanced 
mucosal immunity at the time of hatch in chickens. These findings are also supported by recent 
studies that show CpG-ODN induce pro-inflammatory cytokine gene upregulation (304) as well 
as their contribution to supress Campylobacter colonization in the gut (305) in chickens. The 
conditioning of mucosal surfaces by CpG-ODN to face pathogens more effectively are proven by 
these findings.  
Cytokines are well known as immune mediators, acting on immune cells and   promoting 
induction of other cytokines (154). They are also modulators of recruiting immune cells to 
inflammatory sites (81) and causing upregulation of costimulatory molecules on APCs, resulting 
in optimal interaction of APCs with naive CD4+ and CD8+ T cells (137). Our flow cytometry data 
showed a significantly enhanced enrichment of macrophages in both spleen and lungs of CpG-
ODN treated embryo and chicks, and these macrophages in CpG-ODN treated chicks were 
expressing significantly higher CD40; whereas, CD86 was not very different from saline control. 
The changes in APCs of CpG-ODN treated chickens can be explained by their cytokine profiles. 
We specifically noted the upregulation of Litaf gene expression throughout the experiment, a 
cytokine that have shown to contribute to the upregulation of CD40 (267, 287). Moreover, it has 
been shown that CD40 expressing APCs are required to efficiently activate, cause maturation and 
proliferation of T cells in mice (111). Our findings also show that CpG-ODN promote the 
enrichment of T-cell immunological niches in both spleen and lung in chicken. We also evaluated 
the thymic T cell population and observed high expression of both CD4+ and CD8+ in the 
thymocytes following CpG-ODN treatment, suggesting a potentially increased thymic output. 
Thus, we suggest that the increase of T cells in both spleen and lung following CpG-ODN 
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treatment may be due to enhanced recruitment of T cells and increase thymic output. Interestingly, 
previous studies have shown that TNFα factor is constitutively synthesized in the thymus (97) and 
promotes T cell development (268). Thus, CpG-ODN induced upregulation of Litaf gene can be 
acknowledged for playing a significant role in enriching the immune compartment in chickens. 
However, further detailed studies are needed for a proper understanding of CpG-ODN induced 
Litaf action in chickens. All these immunological changes can be explained as a cascade of events 
interconnected and priming the immune system of chickens at the time of hatch, which also 
explains the protection against infections shown in previous studies in neonatal chickens.  
We recently report that intrapulmonary delivery of CpG-ODN in chickens resulted in 
enhanced infiltration of inflammatory cells in the pulmonary parenchyma (106). In the third 
chapter of this thesis, we investigated immune cell recruitment at the time of hatch, following 
different doses of CpG-ODN (5, 10, 25, 50 µg of CpG-ODN per embryo) by in ovo delivery in 
chickens and further examined the correlation of their immunological profiles with the protection 
against E. coli infection in chicks. We selected spleen, the main secondary lymphoid organ, which 
represent systemic changes, and lung, which represent a local mucosal change and one of the most 
common sites for pathogen encounter. Our results showed a CpG-ODN-dose-dependent increase 
in the number of macrophages/monocytes in the immunological niches in both spleen and lungs. 
Moreover, we observed an increase in CD40 expression with different doses of CpG-ODN. CD40 
is recognised as an important molecule involved in many immune functions such as, B cell 
proliferation, differentiation, T cell proliferation, monocyte and dendritic cell growth and cytokine 
production (7, 31, 169). Moreover, we observed a significant increase in MHCII-expressing APCs 
with 25 and 50 µg of in ovo CpG-ODN in both lung and spleen, which suggest enhanced antigen 
presentation ability resulting in effective and rapid pathogen clearance. These findings suggest that 
the immunological niches in CpG-ODN treated chicks are well equipped with mature APCs with 
the ability to activate effector immune cells such as CD4+ and CD8+ T lymphocytes. We also 
report a dose-dependent increase in CD4+ and CD8+ T cell populations, which play important role 
in humoral and cell-mediated immunity following CpG-ODN treatment. In order to evaluate the 
correlation of immunological changes with immune-protection against E. coli infection, we 
assessed the survival (protection level) following a lethal E. coli challenge. We found significant 
survival levels in birds that received 25 and 50 µg of CpG-ODN compared to the saline control, 
but not birds that received 10 µg or less CpG-ODN. The changes in immune profiles correlated 
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with survival data, where 25 µg and 50 µg of CpG-ODN demonstrated significantly higher 
MHCII-expression on APCs. CD40 expression on APCs and T cell populations correlated with 
their ability to resist E. coli infection at the time of hatch. Birds that received 10 µg or less CpG-
ODN showed enhanced immune profiles, but were not significantly different from the saline 
control. Our findings revealed that CpG-ODN not only stimulates immune cells but also 
remarkably enriches the immunological niche, making neonatal chicks well prepared to tackle 
pathogenic insults at the time of hatch. 
Although in ovo delivery CpG-ODN showed immunoprotective effects on neonatal 
chickens against bacterial infections, there are few optimizations to be maid prior to use in poultry 
hatcheries. Among them, the dose of CpG-ODN is important since amount of CpG-ODN reaching 
the chicken embryo is  limited due to protective substances such as nucleases of the amniotic fluid 
surrounding the embryo. Although CpG-ODN reaches the embryo through the mouth, it is difficult 
to estimate amount of CpG-ODN needed to stimulate intracellular receptors such as TLR21 of 
APCs and immune cells of mucosal surfaces of lungs and systemic organs such as the spleen. 
Nanoparticle based delivery systems are often considered as ways to overcome these challenges. 
A successful CpG-ODN delivering system will condense and encapsulate the ODN, while 
protecting it from neucleases (325) and facilitate cellular uptake by acting as a nano-carrier (349). 
We have evaluated the possibility of using two types of in ovo CpG-ODN delivery systems in 
broiler chickens. The fourth chapter of this thesis reveal data on potentiation of CpG-ODN immune 
stimulatory action when formulated with either a lipid based delivery system or CNT based 
delivery system. Survival of birds were significantly higher with CpG-ODN formulations used, 
compared to CpG-ODN alone and saline groups following an E. coli challenge. Moreover, these 
formulations did not cause any adverse effects on birds throughout the trial period and until they 
reached their processing age (42 days of age). These data revealed that the lipid surfactant and 
CNT delivery systems that we used can safely enhance the immune protective effect of CpG-ODN 
against an E. coli infection in neonatal broiler chickens. 
Findings of our research shows that in ovo CpG-ODN not only protect chickens from 
neonatal bacterial infections but also possible to enhance the effectiveness of poultry vaccines that 
given in neonatal life of broiler chickens. Several vaccines are given to chickens at day 18 of 
incubation or at the time of hatch at hatcheries. Developing a desired immunity in neonatal 
chickens against vaccine antigens can be a challenge due to their immaturity of the immune system 
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or due to lack of sensitization of immune system with antigens at hatch. We have shown a 
maturation and enrichment of immune compartments following in ovo delivery of CpG-ODN 
treatment and this can be used as beneficial prerqisite of neonatal vaccine delivery. Therefore, 
CpG-ODN treated chicken immune systems will be more receptive to vaccine antigens, resulting 
in rapid immune responses and immunological memory. This will be particularly be beneficial for 
vaccines against diseases like necrotic enteritis, where single vaccinations at day one are non-
protective in broiler chickens, (221) and quicker, effective immune responses are desired. We also 
highlight the role of CpG-ODN induced Litaf in modulating many aspects of immune functions in 
our study. However, further studies are needed for better understanding and confirmation of the 
TLR21-Litaf-mediated immune enrichment in chickens. This can be done as in other laboratory 
animals although knockout chicken models are rare but not impossible (272). A Litaf gene 
knockout chicken model may be an ideal model to study the role of CpG-ODN induced Litaf in 
maturation and enhancement of immune cells. Exploring the expression levels of TLR21 gene or 
TLR21 receptor itself following CpG-ODN treatment will also confirm the involvement of this 
TLR in chicken immune system.  
In conclusion, we reveal that in ovo delivery of CpG-ODN provides protection in neonatal 
chicks against E. coli infection by eliciting cytokine responses, as well as enriching immunological 
niches in spleen and lungs. Finally, our findings on optimization of CpG-ODN and enrichment of 
immune cells and cytokines in differenet immune compartments and its correlation with protection 
of neonatal broiler chickens against E. coli infection provides importance of dose of CpG-ODN 
when CpG-ODN is used under field conditions. Furthermore, we have demonstrated formulation 
systems such as CNTs or liposomes to potentiate the immune stimulation of  CpG-ODN and shown 
their safety in the poultry industry as an alternative to antibiotic. Although we have demonstrated 
utility of CpG-ODNs under laboratory conditions it is necessary to conduct field trials in order to 
validate our observations under field conditions. 
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